

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 30, 2004, 16:30:56 ; Search time 1 Seconds
(without alignments)
1.712 Million cell updates/sec

Title: US-09-503-596-2

Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataactttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 57 seqs, 1350 residues

Total number of hits satisfying chosen parameters: 114

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 57 summaries

Database : rng2.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	65	10.3	65	1	Human fatty acid b
2	60	9.5	60	1	Human spliced tran
3	51	8.0	60	1	Probe related to t
4	50	7.9	50	1	Human leukocyte ge
5	33	5.2	33	1	Probe #17 used in
6	33	5.2	33	1	ap2 mRNA specific
7	33	5.2	33	1	Probe #17, used in
8	29	4.6	29	1	Probe #16, used in
9	29	4.6	29	1	ap2 mRNA specific
10	29	4.6	29	1	Probe #16, used in
11	26	4.1	26	1	Probe #15, used in
12	26	4.1	26	1	ap2 mRNA specific
13	26	4.1	26	1	Probe #15, used in
14	26	4.1	26	1	Primer ap2 antisense
15	24.2	3.8	30	1	Mouse ap2 hybridis
16	24	3.8	24	1	Probe #19 used in
17	24	3.8	24	1	ap2 mRNA specific
18	24	3.8	24	1	Probe #19, used in
19	23	3.6	23	1	Probe #18 used in
20	23	3.6	23	1	ap2 mRNA specific
21	23	3.6	23	1	Probe #18, used in
22	20	3.2	20	1	ap2 mRNA amplifin
23	20	3.2	20	1	Human fatty acid b
24	20	3.2	20	1	Human fatty acid b
25	20	3.2	20	1	afABP cDNA amplif
26	20	3.2	20	1	ADP29732
27	20	3.2	20	1	Human ap2 gene amp
28	19	3.0	19	1	ap2 mRNA amplifin
29	19	3.0	19	1	ADP25483
30	19	3.0	19	1	ap2 mRNA specific
31	19	3.0	19	1	Probe #20, used in
32	19	3.0	20	1	Human ap2 gene amp
33	18.8	3.0	22	1	Forward primer fla

34	18	2.8	18	1	Human fatty acid b
35	16.8	2.6	20	1	Human oligonucleot
36	16.8	2.6	21	1	Novel fatty acid-b
37	15.4	2.4	17	1	Human H-Ras DNazym
38	15.4	2.4	18	1	Human H-Ras DNazym
39	14.8	2.3	18	1	Human H-Ras DNazym
40	14.8	2.3	18	1	Human H-Ras DNazym
41	14.4	2.3	17	1	Human H-Ras DNazym
42	14.4	2.3	17	1	Human H-Ras DNazym
43	14.4	2.3	17	1	Human H-Ras DNazym
44	14.4	2.3	17	1	Human H-Ras DNazym
45	14.4	2.3	17	1	Human H-Ras DNazym
46	14.4	2.3	17	1	Human H-Ras DNazym
47	14.4	2.3	17	1	Human H-Ras DNazym
48	13.8	2.2	17	1	Human H-Ras DNazym
49	13.8	2.2	17	1	Human H-Ras DNazym
50	13.8	2.2	17	1	Human H-Ras DNazym
51	13.8	2.2	17	1	Human H-Ras DNazym
52	13.8	2.2	17	1	Human H-Ras DNazym
53	13.8	2.2	17	1	Human H-Ras DNazym
54	13.8	2.2	17	1	Human H-Ras DNazym
55	13.4	2.1	15	1	Human H-Ras DNazym
56	13.4	2.1	16	1	Human H-Ras DNazym
57	13.4	2.1	16	1	Human H-Ras DNazym

ALIGNMENTS

RESULT 1
AAD48759
ID AAD48759 standard; RNA; 65 BP.
XX AC AAD48759;
XX DT 07-MAR-2003 (first entry)
XX DE Human fatty acid binding protein 2 (FABP-2) RNA fragment #1.
XX KW Human; RNA binding molecule; fatty acid binding protein 2; FABP-2; ss.
XX OS Homo sapiens.
XX PN WO2002081748-A1.
XX PD 17-OCT-2002.
XX PF 04-APR-2002; 2002WO-SE000677.
XX PR 05-APR-2001; 2001SE-00001218.
XX PS 05-APR-2001; 2001US-0281384P.
XX PT (BIOV-) BIOVITRUM AB.
XX PI Ekblom J;
XX WPI; 2003-058568/05.
XX PT Identifying RNA-binding molecule by predicting structure of RNA fragment, synthesizing DNA fragment corresponding to predicted RNA structure, performing reporter gene assay after placing the DNA upstream of reporter gene.
XX Claim 12; Page 28; 35pp; English.
XX The present invention relates to a method of identifying RNA-binding molecule comprising predicting the structure of RNA-fragment, selecting suitable predicted RNA fragment with an individual stem, synthesizing a DNA-fragment corresponding to the RNA fragment, inserting the DNA fragment in upstream proximity of reporter assay gene to form reporter construct and performing a reporter gene assay which detects interaction between a molecule to be tested for RNA-binding and RNA fragment of the reporter construct. The method is useful for identifying an RNA binding

CC	predicting therapeutic outcome, determining prognosis for a patient,
CC	predicting disease complications in an individual or monitoring response
CC	to treatment in an individual. The diseases include cardiac allograft
CC	rejection, kidney allograft rejection, liver allograft rejection,
CC	atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC	rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX	
XX	Sequence 50 BP; 11 A; 10 C; 8 G; 21 T; 0 U; 0 Other;
XX	
XX	Query March 7.9%; Score 50; DB 1; Length 50;
XX	Best Local Similarity 100.0%; Freq. No. 0.94;
XX	Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	539 TTGTGTTTTCCTGATTAGCAAGCAAGTAATTTTCCCAAGCTGATT 588
Db	1 TTGTGTTTTCCTGATTAGCAAGCAAGTAATTTTCCCAAGCTGATT 50

RESULT 3
AAD25480/c
ID AAD25480 standard; DNA; 33 BP.

AC	AD23480;
XX	
DT	26-MAR-2002 (first entry)

XX Benzoxazincine derivative; glucose metabolism; lipid metabolism; NIDDM;
 XX PPA; gamma; geroprotection; insulin; activated receptor gamma; hsp90;
 XX n; xanthine oxidase; xanthine oxidase; xanthine oxidase; xanthine oxidase;
 XX atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 XX ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
 XX reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.
 QS Unidentified.

12-MAY-2000; 2000US-0203859P.
PR
PR 11-MAY-2001; 2001US-00853798.
XX
PA (ORTH) ORTHO-MCNEIL PHARM IN

XX
XX
PA (QETH) QETHO-MCNEIL PHARM IN
20105-00000, 20105-00000, 20105-00000

Use of benzoxazinone derivatives for treating a subject suffering from a disorder in glucose and lipid metabolism such as non-insulin dependant diabetes mellitus or obesity.

PT disorder in glucose and lipid metabolism such as non-insulin dependent diabetes mellitus or obesity.

diabetes mellitus or obesity.

Example 2: Page 34: 45pp: Eng

also relates to pharmaceutical compositions comprising benzoxazine derivatives and methods for treating the onset of a disorder in glucose and lipid metabolism, preferably a condition of reduced insulin sensitivity such as non-insulin dependant diabetes mellitus (NIDDM).

CC disease, irritative bowel disorder, inflammation and catarrh; the
CC present sequence is a probe designed to anneal to the ap2 mRNA and
CC function in the bDNA mRNA detection system. This probe used in the ap2
CC assay for antagonist which is used in the exemplification of the
CC invention
XX Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other; 50

Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

Query Match 5.2%; Score 33; DB 1; Length 33;
 Best Local Similarity 100.0%; Pred. No. 6.6;
 Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AAAAATCTGAGATTTCCTTCATCTGGCCAG 269
 DB 33 AAAAATCTGAGATTTCCTTCATCTGGCCAG 1

RESULT 6
 ID AAI68020/c
 XX AAI68020 standard; DNA; 33 BP.
 AC AAI68020;
 XX DT 13-MAR-2002 (first entry)
 DE ap2 mRNA specific oligonucleotide probe.
 XX KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
 KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
 KW nephrotropic; ophthalmological; antiarteriosclerotic; cyostatic;
 KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
 KW PPARGamma; probe; ap2; ss.
 XX OS Synthetic.
 XX WO200187861-A2.
 XX PD 22-NOV-2001.
 XX PF 11-MAY-2001; 2001WO-US015377.
 XX PR 12-MAY-2000; 2000US-0203861P.
 XX PR 11-MAY-2001; 2001US-00854368.
 XX PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX PI Burris TP, Demarest KT, Combs DW, Rybczynski PU, Turchi IU;
 XX WPI; 2002-082971/11.
 XX PT Use of benzoxazinone derivatives for treating a subject suffering from a
 PT condition associated with peroxisome proliferator activated receptor
 PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
 XX PS Example 7; Page 29; 46pp; English.
 XX CC The invention provides methods of treating a subject suffering from a
 CC condition associated with peroxisome proliferator activated receptor
 CC gamma (PPARGamma) activity that involves administering a benzoxazinone
 CC compound of a specified formula to the subject. The method is useful for
 CC treating and inhibiting in a subject the onset of a condition associated
 CC with PPARGamma activity such as a condition of reduced insulin
 CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
 CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
 CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
 CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
 CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
 CC antagonists
 XX SQ Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

Query Match 5.2%; Score 33; DB 1; Length 33;
 Best Local Similarity 100.0%; Pred. No. 6.6;
 Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AAAAATCTGAGATTTCCTTCATCTGGCCAG 269
 DB 33 AAAAATCTGAGATTTCCTTCATCTGGCCAG 1

RESULT 7
 AAD24704/c
 ID AAD24704 standard; DNA; 33 BP.
 XX AC AAD24704;
 XX DT 12-MAR-2002 (first entry)
 XX DE Probe #17, used in ap2 assay for antagonist.
 XX KW 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
 KW PPARG gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
 KW anorectic; nephrotropic; ophthalmological; cyostatic; hypotensive;
 KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
 KW ap2 mRNA; ss.
 XX OS Unidentified.
 XX WO200187862-A2.
 XX PD 22-NOV-2001.
 XX PF 11-MAY-2001; 2001WO-US015383.
 XX PR 12-MAY-2000; 2000US-0203860P.
 XX PR 11-MAY-2001; 2001US-00854302.
 XX PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX PI Burris TP, Combs DW, Rybczynski PU;
 XX WPI; 2002-055671/07.
 XX PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
 PT suffering from a disorder in glucose and lipid metabolism e.g. non-
 PT insulin dependant diabetes mellitus and obesity.
 XX PS Example 38; Page 58; 76pp; English.
 XX CC The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
 CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
 CC antagonists. The invention also relates to compositions comprising such
 CC compounds and methods for treating or inhibiting the onset of a disorder
 CC in glucose and lipid metabolism, preferably a condition of reduced
 CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
 CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
 CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present DNA sequence is a probe which is designed to anneal to ap2 mRNA
 CC and function in the bDNA mRNA detection system. This probe is used in ap2
 CC assay for antagonist in the exemplification of the invention
 XX SQ Sequence 33 BP; 9 A; 6 C; 7 G; 11 T; 0 U; 0 Other;

Query Match 5.2%; Score 33; DB 1; Length 33;
 Best Local Similarity 100.0%; Pred. No. 6.6;
 Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AAAAATCTGAGATTTCCTTCATCTGGCCAG 269
 DB 33 AAAAATCTGAGATTTCCTTCATCTGGCCAG 1

RESULT 8
 AAD25479/c
 ID AAD25479 standard; DNA; 29 BP.
 XX AC AAD25479;
 XX DT 26-MAR-2002 (first entry)

```

XX DE Probe #16 used in ap2 assay for antagonist.
XX KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
XX KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
XX KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
XX KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
XX KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
XX KW reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.
XX OS Unidentified.
XX OS WO200187860-A2.
XX PN 22-NOV-2001.
XX PD 11-MAY-2001; 2001WO-US015320.
XX PF 12-MAY-2000; 2000US-0203859P.
XX PR 11-MAY-2001; 2001US-00853798.
XX XX (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PA Burris TP, Rybczynski PJ;
XX PI WPI; 2002-082970/11.
XX DR Use of benzoxazinone derivatives for treating a subject suffering from a
XX PT disorder in glucose and lipid metabolism such as non-insulin dependant
XX PT diabetes mellitus or obesity.
XX XX Example 2; Page 34; 45pp; English.
XX PS The invention relates to benzoxazinone derivatives useful as peroxisome
XX CC proliferator activated receptor (PPAR) gamma modulators. The invention
XX CC also relates to pharmaceutical compositions comprising benzoxazinone
XX CC derivatives and methods for treating the onset of a disorder in glucose
XX CC and lipid metabolism, preferably a condition of reduced insulin
XX CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
XX CC polycystic ovary syndrome (PCOS), retinopathy, atherosclerosis,
XX CC diseases, irritable bowel disorder, inflammation and cataract. The
XX CC present sequence is a probe designed to anneal to the ap2 mRNA and
XX CC function in the bDNA mRNA detection system. This probe used in the ap2
XX CC assay for antagonist which is used in the exemplification of the
XX CC invention
XX SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB |||||
29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 9
AA168019/c
ID AA168019 standard; DNA; 29 BP.
XX AC AA168019;
XX XX 13-MAR-2002 (first entry)
XX DT
XX DE ap2 mRNA specific oligonucleotide probe.
XX XX Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
XX KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
XX KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
XX KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
XX KW PPARgamma; probe; ap2; ss.

```

```

XX OS Synthetic.
XX OS WO200187861-A2.
XX PN 22-NOV-2001.
XX PD 11-MAY-2001; 2001WO-US015377.
XX PF 12-MAY-2000; 2000US-0203861P.
XX PR 11-MAY-2001; 2001US-00854368.
XX XX (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PA Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
XX PI WPI; 2002-082971/11.
XX DR Use of benzoxazinone derivatives for treating a subject suffering from a
XX PT condition associated with peroxisome proliferator activated receptor
XX PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX XX Example 7; Page 29; 46pp; English.
XX PS The invention provides methods of treating a subject suffering from a
XX CC condition associated with peroxisome proliferator activated receptor
XX CC gamma (PPARG) activity that involves administering a benzoxazinone
XX CC compound of a specified formula to the subject. The method is useful for
XX CC treating and inhibiting in a subject the onset of a condition associated
XX CC with PPARG gamma activity such as a condition of reduced insulin
XX CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
XX CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
XX CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
XX CC disorder, inflammation and cataract. Sequences AA168004-023 represent
XX CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
XX CC antagonists
XX SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB |||||
29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 10
AAD24703/c
ID AAD24703 standard; DNA; 29 BP.
XX AC AAD24703;
XX XX 12-MAR-2002 (first entry)
XX DT
XX DE Probe #16, used in ap2 assay for antagonist.
XX XX 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
XX KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
XX KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
XX KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
XX KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
XX KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
XX KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
XX KW ap2 mRNA; ss.
XX XX Unidentified.
XX OS WO200187862-A2.
XX PN 22-NOV-2001.
XX PD
XX XX

```

PF 11-MAY-2001; 2001WO-US015383.
 XX
 PR 12-MAY-2000; 2000US-0203860P.
 PR 11-MAY-2001; 2001US-00854302.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX
 PI Burris TP, Combs DW, Rybczynski PJ;
 XX
 DR WPI; 2002-055671/07.
 XX
 XX Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
 PT suffering from a disorder in glucose and lipid metabolism e.g. non-
 PT insulin dependant diabetes mellitus and obesity.
 XX
 PS Example 38; Page 58; 76pp; English.
 XX
 CC The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
 CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
 CC antagonists. The invention also relates to compositions comprising such
 CC compounds and methods for treating or inhibiting the onset of a disorder
 CC in glucose and lipid metabolism, preferably a condition of reduced
 CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
 CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
 CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present DNA sequence is a probe which is designed to anneal to ap2
 CC and function in the bDNA mRNA detection system. This probe is used in ap2
 CC assay for antagonist in the exemplification of the invention
 XX
 SQ Sequence 29 BP; 10 A; 3 C; 6 G; 10 T; 0 U; 0 Other;
 Query Match 4.6%; Score 29; DB 1; Length 29;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
 DB 29 TGATCACCATTAAATCTGAAAGTACCTTT 1
 RESULT 11
 AAD25478/c
 ID AAD25478 standard; DNA; 26 BP.
 AC AAD25478;
 XX
 DT 26-MAR-2002 (first entry)
 DE
 DE Probe #15 used in ap2 assay for antagonist.
 XX
 KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
 KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
 KW reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.
 XX
 OS Unidentified.
 XX
 PN WO200187860-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 11-MAY-2001; 2001WO-US015320.
 XX
 PR 12-MAY-2000; 2000US-0203859P.
 PR 11-MAY-2001; 2001US-00853798.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX
 PI Burris TP, Rybczynski PJ;
 XX

DR WPI; 2002-082970/11.
 XX
 XX Use of benzoxazinone derivatives for treating a subject suffering from a
 PT disorder in glucose and lipid metabolism such as non-insulin dependant
 PT diabetes mellitus or obesity.
 XX
 XX Example 2; Page 34; 45pp; English.
 XX
 CC The invention relates to benzoxazinone derivatives useful as peroxisome
 CC proliferator activated receptor (PPAR) gamma modulators. The invention
 CC also relates to pharmaceutical compositions comprising benzoxazinone
 CC derivatives and methods for treating the onset of a disorder in glucose
 CC and lipid metabolism, preferably a condition of reduced insulin
 CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
 CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
 CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present sequence is a probe designed to anneal to the ap2 mRNA and
 CC function in the bDNA mRNA detection system. This probe is used in the ap2
 CC assay for antagonist which is used in the exemplification of the
 CC invention
 XX
 SQ Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 4.1%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 90 AAATCTGCTCCAGTGAAGAACTTTGA 115
 DB 26 AAATCTGCTCCAGTGAAGAACTTTGA 1
 RESULT 12
 AAI68018/c
 ID AAI68018 standard; DNA; 26 BP.
 AC AAI68018;
 XX
 DT 13-MAR-2002 (first entry)
 DE
 DE ap2 mRNA specific oligonucleotide probe.
 KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
 KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
 KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
 KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
 KW PPARgamma; probe; ap2; ss.
 XX
 OS Synthetic.
 XX
 PN WO200187861-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 11-MAY-2001; 2001WO-US015377.
 XX
 PR 12-MAY-2000; 2000US-0203861P.
 PR 11-MAY-2001; 2001US-00854368.
 XX
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX
 PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
 XX
 DR WPI; 2002-082971/11.
 XX
 XX Use of benzoxazinone derivatives for treating a subject suffering from a
 PT condition associated with peroxisome proliferator activated receptor
 PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
 XX
 PS Example 7; Page 29; 46pp; English.
 XX
 XX The invention provides methods of treating a subject suffering from a

CC condition associated with peroxisome proliferator activated receptor
 CC gamma (PPARGgamma) activity that involves administering a benzoxazinone
 CC compound of a specified formula to the subject. The method is useful for
 CC treating and inhibiting in a subject the onset of a condition associated
 CC with PPARGgamma activity such as a condition of reduced insulin
 CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
 CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
 CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
 CC disorder, inflammation and cataract. Sequences AAF68004-023 represent
 CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
 CC antagonists
 CC
 SQ Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 4.1%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAACACTTTGA 115
 DB 26 AAACCTGTCTCCAGTGAACACTTTGA 1

RESULT 13
 AAD24702/c
 ID AAD24702 standard; DNA; 26 BP.

XX AAD24702;

DT 12-MAR-2002 (first entry)

DE Probe #15, used in ap2 assay for antagonist.

XX 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
 KW PPARG gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
 KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
 KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
 KW ap2 mRNA; ss.

XX Unidentified.

XX WO200187862-A2.

XX 22-NOV-2001.

XX 11-MAY-2001; 2001WO-US015383.

XX 12-MAY-2000; 2000US-0203860P.

PR 11-MAY-2001; 2001US-00854302.

XX (ORTH) ORTHO-MCNEIL PHARM INC.

XX Burris TP, Combs DW, Rybczynski PJ;

XX WPI; 2002-055671/07.

XX Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
 PT suffering from a disorder in glucose and lipid metabolism e.g. non-
 PT insulin dependant diabetes mellitus and obesity.

PS Example 38; Page 58; 76pp; English.

XX The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
 CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
 CC antagonists. The invention also relates to compositions comprising such
 CC compounds and methods for treating or inhibiting the onset of a disorder
 CC in glucose and lipid metabolism, preferably a condition of reduced
 CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
 CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
 CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart

CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present DNA sequence is a probe which is designed to anneal to ap2 mRNA
 CC and function in the bDNA mRNA detection system. This probe is used in ap2
 CC assay for antagonist in the exemplification of the invention
 XX
 SQ Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 4.1%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAACACTTTGA 115
 DB 26 AAACCTGTCTCCAGTGAACACTTTGA 1

RESULT 14
 ACC44484/c
 ID ACC44484 standard; DNA; 26 BP.

XX ACC44484;

DT 29-AUG-2003 (first entry)

DE Primer ap2 antisense for RNA analysis in activated preadipocyte cells.

XX Primer; human; telomerase reverse transcriptase; adipogenic capacity;
 KW primary preadipocyte cell; adipogenesis; obesity; adipocytokine; ss; PCR;
 KW anorectic; adiponectin; insulin.

XX Homo sapiens.

XX WO2003031640-A2.

XX 17-APR-2003.

XX 07-OCT-2002; 2002WO-US031635.

XX 06-OCT-2001; 2001US-0327650P.

PR 06-OCT-2001; 2001US-0327651P.

XX (BOST-) BOSTON MEDICAL CENT CORP.

XX Kirkland J, Tchkonja T;

XX WPI; 2003-421278/39.

XX New primary preadipocyte strain expressing telomerase reverse
 PT transcriptase, useful in research applications, screening assays,
 PT clinical applications, and in the administration of therapeutic agents,
 PT particularly for obesity.

PS Disclosure; Page 21; 53pp; English.

XX The invention relates to the generation of primary preadipocyte cell
 CC strains that express telomerase reverse transcriptase (TERT- the
 CC catalytic subunit of telomerase), and maintain and/or enhance replicative
 CC potential and maintain adipogenic capacity of the cell. In order to
 CC detect adipocyte replication and adipogenicity, RNA analysis of a number
 CC of genes were carried out to detect cell proliferation. This sequence
 CC represents a primer used to detect RNA expression of the Ap2 gene. The
 CC cell strain can be used in research to study all aspect of adipogenesis,
 CC especially in relation to researching treatments for e.g. obesity. The
 CC cell can also be used to identify adipogenesis modulators for use as
 CC therapeutic agents such as hormones, growth factors, cytokines, enzymes,
 CC cholesterol binding proteins, cholesterol removing proteins or their
 CC combinations. Alternatively, the therapeutic agent may be an
 CC adipocytokine, preferably adiponectin, or insulin

XX Sequence 26 BP; 9 A; 3 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 4.1%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 14;

DD 1 ATGTGTATCCCTTTGTGGAAACCTGGAA 29
 RESULT 16
 AAD25482/c
 ID AAD25482 standard; DNA; 24 BP.
 XX
 AC AAD25482;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Probe #19 used in ap2 assay for antagonist.
 XX
 KW Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
 KW PAR gamma; peroxisome proliferator activated receptor gamma; therapy;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
 KW reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.
 OS Unidentified.
 XX
 EN WO200187860-A2.
 XX
 PD 22-NOV-2001.
 XX
 PD 11-MAY-2001; 2001WO-US015320.
 XX
 PR 12-MAY-2000; 2000US-0203859P.
 PR 11-MAY-2001; 2001US-00853798.
 XX
 XX (ORTH) ORTHO-MCNEIL PHARM INC.
 PA
 PI Burris TP, Rybczynski PJ;
 PI
 DR WPI; 2002-082970/11.
 XX
 PT Use of benzoxazinone derivatives for treating a subject suffering from a
 PT disorder in glucose and lipid metabolism such as non-insulin dependant
 PT diabetes mellitus or obesity.
 PS
 PS Example 2; Page 34; 45pp; English.
 XX
 CC The invention relates to benzoxazinone derivatives useful as peroxisome
 CC proliferator activated receptor (PPAR) gamma modulators. The invention
 CC also relates to pharmaceutical compositions comprising benzoxazinone
 CC derivatives and methods for treating the onset of a disorder in glucose
 CC and lipid metabolism, preferably a condition of reduced insulin
 CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
 CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
 CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present sequence is a probe designed to anneal to the ap2 mRNA and
 CC function in the bDNA mRNA detection system. This probe used in the ap2
 CC assay for antagonist which is used in the exemplification of the
 CC invention
 XX
 SQ Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;
 Query Match 3.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred No. 17;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 293 TGACAGGAAGTCAAGAGCACCAT 316
 XX
 bB 24 TGACAGGAAGTCAAGAGCACCAT 1
 XX

XX 13-MAR-2002 (first entry)
 XX ap2 mRNA specific oligonucleotide probe.
 XX Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
 XX non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
 XX nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
 XX hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
 XX PPARgamma; probe; ap2; ss.
 XX Synthetic.
 OS WO200187861-A2.
 PN 11-MAY-2001; 2001US-00854368.
 XX (ORTH) ORTHO-MCNEIL PHARM INC.
 XX Burris TP, Demarest KT, Combs DW, Rybczynski PU, Turchi IJ;
 XX WPI; 2002-082971/11.
 XX Use of benzoxazinone derivatives for treating a subject suffering from a
 PT condition associated with peroxisome proliferator activated receptor
 PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
 XX Example 7; Page 29; 46pp; English.
 XX The invention provides methods of treating a subject suffering from a
 CC condition associated with peroxisome proliferator activated receptor
 CC gamma (PPARgamma) activity that involves administering a benzoxazinone
 CC compound of a specified formula to the subject. The method is useful for
 CC treating and inhibiting in a subject the onset of a condition associated
 CC with PPARgamma activity such as a condition of reduced insulin
 CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
 CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
 CC syndrome, hypertension, ischaemia, stroke, heart diseases, irritable bowel
 CC disorder, inflammation and cataract. Sequences A158004-023 represent
 CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
 CC antagonists
 XX Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;
 SQ Query Match 3.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 17;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 293 TGACAGGAAAGTCAAGAGCACCAT 316
 Db 24 TGACAGGAAAGTCAAGAGCACCAT 1
 RESULT 18
 AAD24706/c
 ID AAD24706 standard; DNA; 24 BP.
 XX AAD24706;
 XX 12-MAR-2002 (first entry)
 XX Probe #19, used in ap2 assay for antagonist.
 XX 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
 KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;

KW anorectic; nephrotropic; ophthalmological; cytostatic; hypotensive;
 KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
 KW ap2 mRNA; ss.
 OS Unidentified.
 XX WO200187862-A2.
 XX 22-NOV-2001.
 XX 11-MAY-2001; 2001WO-US015383.
 XX 12-MAY-2000; 2000US-0203860P.
 XX 11-MAY-2001; 2001US-00854302.
 XX (ORTH) ORTHO-MCNEIL PHARM INC.
 XX Burris TP, Combs DW, Rybczynski PU;
 XX WPI; 2002-055671/07.
 XX Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
 PT suffering from a disorder in glucose and lipid metabolism e.g. non-
 PT insulin dependant diabetes mellitus and obesity.
 XX Example 38; Page 58; 76pp; English.
 XX The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
 CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
 CC antagonists. The invention also relates to compositions comprising such
 CC compounds and methods for treating or inhibiting the onset of a disorder
 CC in glucose and lipid metabolism, preferably a condition of reduced
 CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
 CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
 CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present DNA sequence is a probe which is designed to anneal to ap2 mRNA
 CC and function in the bDNA mRNA detection system. This probe is used in ap2
 CC assay for antagonist in the exemplification of the invention
 XX Sequence 24 BP; 3 A; 6 C; 5 G; 10 T; 0 U; 0 Other;
 SQ Query Match 3.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 17;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 293 TGACAGGAAAGTCAAGAGCACCAT 316
 Db 24 TGACAGGAAAGTCAAGAGCACCAT 1
 RESULT 19
 AAD25481/c
 ID AAD25481 standard; DNA; 23 BP.
 XX AAD25481;
 XX 26-MAR-2002 (first entry)
 XX Probe #18 used in ap2 assay for antagonist.
 XX Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
 KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
 KW reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.
 OS Unidentified.
 XX WO200187860-A2.
 XX 22-NOV-2001.

```

XX PF 11-MAY-2001; 2001WO-US015320.
XX PF 12-MAY-2000; 2000US-0203859P.
XX PR 11-MAY-2001; 2001US-00853798.
XX PA (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PI Burris TP, Rybczynski PJ;
XX DR WPI; 2002-082970/11.
XX PT Use of benzoxazinone derivatives for treating a subject suffering from a
XX PT disorder in glucose and lipid metabolism such as non-insulin dependant
XX PT diabetes mellitus or obesity.
XX PS Example 2; Page 34; 45pp; English.
XX CC The invention relates to benzoxazinone derivatives useful as peroxisome
XX CC proliferator activated receptor (PPAR) gamma modulators. The invention
XX CC also relates to pharmaceutical compositions comprising benzoxazinone
XX CC derivatives and methods for treating the onset of a disorder in glucose
XX CC and lipid metabolism, preferably a condition of reduced insulin
XX CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
XX CC obesity, neuropathy, retinopathy, hypertension, atherosclerosis,
XX CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
XX CC diseases, irritable bowel disorder, inflammation and cataract. The
XX CC present sequence is a probe designed to anneal to the ap2 mRNA and
XX CC function in the bDNA mRNA detection system. This probe used in the ap2
XX CC assay for antagonist which is used in the exemplification of the
XX CC invention
XX SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 GAATTTGACGAGTCACTGCAGA 292
DB 23 GAATTTGACGAGTCACTGCAGA 1

RESULT 20
AAI68021/c
ID AAI68021 standard; DNA; 23 BP.
XX AC AAI68021;
XX DT 13-MAR-2002 (first entry)
XX DE ap2 mRNA specific oligonucleotide probe.
XX KW Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
XX KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
XX KW nephrotropic; ophthalmological; antiarteriosclerotic; cytosstatic;
XX KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
XX KW PPARgamma; probe; ap2; ss.
XX OS Synthetic.
XX PN WO200187861-A2.
XX PD 22-NOV-2001.
XX PF 11-MAY-2001; 2001WO-US015377.
XX XX
XX PR 12-MAY-2000; 2000US-0203861P.
XX PR 11-MAY-2001; 2001US-00854368.
XX PA (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PI Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;

```

```

XX XX WPI; 2002-082971/11.
XX PT Use of benzoxazinone derivatives for treating a subject suffering from a
XX PT condition associated with peroxisome proliferator activated receptor
XX PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.
XX PS Example 7; Page 29; 46pp; English.
XX CC The invention provides methods of treating a subject suffering from a
XX CC condition associated with peroxisome proliferator activated receptor
XX CC gamma (PPARGamma) activity that involves administering a benzoxazinone
XX CC compound of a specified formula to the subject. The method is useful for
XX CC treating and inhibiting in a subject the onset of a condition associated
XX CC with PPARGamma activity such as a condition of reduced insulin
XX CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
XX CC neuropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
XX CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
XX CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
XX CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
XX CC antagonists
XX SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 GAATTTGACGAGTCACTGCAGA 292
DB 23 GAATTTGACGAGTCACTGCAGA 1

RESULT 21
AAD24705/c
ID AAD24705 standard; DNA; 23 BP.
XX AC AAD24705;
XX DT 12-MAR-2002 (first entry)
XX DE Probe #18, used in ap2 assay for antagonist.
XX KW 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
XX KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
XX KW non-insulin dependant diabetes mellitus; neuropathy; stroke;
XX KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
XX KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
XX KW anorectic; nephrotropic; ophthalmological; cytosstatic; hypotensive;
XX KW vasotropic; cerebroprotective; cardiant; antiinflammatory; probe;
XX KW ap2 mRNA; ss.
XX OS Unidentified.
XX PN WO200187862-A2.
XX PD 22-NOV-2001.
XX PF 11-MAY-2001; 2001WO-US015383.
XX PR 12-MAY-2000; 2000US-0203860P.
XX PR 11-MAY-2001; 2001US-00854302.
XX PA (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PI Burris TP, Combs DW, Rybczynski PJ;
XX DR WPI; 2002-055671/07.
XX PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
XX PT suffering from a disorder in glucose and lipid metabolism e.g. non-
XX PT insulin dependant diabetes mellitus and obesity.

```

PS Example 38; Page 58; 76pp; English.

XX The patent discloses 4h-Benz(1,4)oxazin-3-one compounds which are useful

CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and

CC antagonists. The invention also relates to compositions comprising such

CC compounds and methods for treating or inhibiting the onset of a disorder

CC in glucose and lipid metabolism, preferably a condition of reduced

CC insulin sensitivity, such as non-insulin dependent diabetes mellitus

CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,

CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart

CC diseases, irritable bowel disorder, inflammation and cataract. The

CC present DNA sequence is a probe which is designed to anneal to ap2 mRNA

CC and function in the bDNA mRNA detection system. This probe is used in ap2

CC assay for antagonist in the exemplification of the invention

XX

SQ Sequence 23 BP; 5 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 3.6%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 19;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 GAATTGACGAAGTCACTGCAGA 292

DB 23 GAATTGACGAAGTCACTGCAGA 1

RESULT 22

AAI66788

ID AAI66788 standard; DNA; 20 BP.

XX AAI66788;

XX

XX 07-JAN-2002 (first entry)

DT

DE ap2 mRNA amplifying RT-PCR primer F.

XX

XX Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;

KW Ihh; sonic hedgehog; Shh; therapeutic; cytostatic; primer; RT-PCR; ss.

KW

XX Synthetic.

OS

XX WO200164238-A2.

PN

XX 07-SEP-2001.

PD

XX 28-FEB-2001; 2001WO-US006450.

PF

XX 29-FEB-2000; 2000US-0186058P.

PR

XX (CURT-) CURIS INC.

PA

XX Zehentner B, Leser-Reiff U, Bartscher H;

PI

XX WPI; 2001-607352/59.

DR

XX Method for regulating formation and/or maintenance of adipocyte tissue by

PT contacting pre-adipocyte or adipocyte cells with a hedgehog polypeptide

PT or ptc therapeutic.

XX

XX Example; Page 77; 132pp; English.

PS

XX The invention provides a method for regulating formation and/or

CC maintenance of adipocyte tissue that comprises contacting pre adipocyte

CC or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The

CC method is used for regulating the growth state of an adipocyte stem/

CC progenitor cell, and treating or preventing disorders of, or surgical or

CC cosmetic repair of, adipocyte tissues, e.g. for treating or preventing

CC hyperplastic or neoplastic conditions affecting adipocyte tissue, such as

CC soft tissue tumors, especially adipose cell tumors, e.g. lipomas,

CC fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or

CC liposarcomas. Hedgehog polypeptides can be used in combination with other

CC therapeutic agents. Sequences AAI66784-793 represent primers used in

CC quantitative RT-PCR of PPARgamma, ap2, Gli, ptc and actin mRNAs, during

CC the course of the invention

XX

SQ Sequence 20 BP; 3 A; 1 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 3.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 25;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 63 ATGTGTGATGCTTTTGTAGG 82

DB 1 ATGTGTGATGCTTTTGTAGG 20

RESULT 23.

ABK87128/c

ID ABK87128 standard; DNA; 20 BP.

XX

XX ABK87128;

XX

XX 07-OCT-2002 (first entry)

DT

XX Human fatty acid binding protein 4, RT-PCR primer #2.

DE

XX Human; endothelial cell-specific molecule 4; ECSM4; neovasculature;

KW imaging vascular endothelium; proliferative disease; cancer; psoriasis;

KW diabetic retinopathy; atherosclerosis; menorrhagia; endothelial damage;

KW tumour neovasculature; cardiac disease; endometriosis; hypoxic condition;

KW angiogenesis; cytostatic; RT-PCR; fatty acid binding protein 4;

KW reverse transcription-PCR; primer; ss.

XX

XX Homo sapiens.

OS

XX WO200236771-A2.

PN

XX 10-MAY-2002.

PD

XX 06-NOV-2001; 2001WO-GB004906.

PF

XX 06-NOV-2000; 2000US-0245566P.

PR

XX 07-MAR-2001; 2001US-0273662P.

XX

XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.

PA

XX Bicknell R, Huminiecki L;

PI

XX WPI; 2002-508120/54.

DR

XX Novel endothelial cell-specific molecule polypeptide 1 or 4, useful for

PT imaging, diagnosing and treating a condition involving vascular

PT endothelium e.g. cancer, cardiac disease, endometriosis, diabetes.

XX

XX Example 1; Page 165; 248pp; English.

PS

XX The present invention relates to endothelial cell-specific molecule 4

CC (ECSM4), and the polynucleotide sequences encoding it. The ECSM4 proteins

CC are useful for imaging vascular endothelium in the body of an individual,

CC and for diagnosing and treating a proliferative disease or condition

CC involving the vascular endothelium (preferably, neovasculature) such as

CC cancer, psoriasis, diabetic retinopathy, atherosclerosis or menorrhagia.

CC The ECSM4 proteins are also useful in the manufacture of diagnostic or

CC prognostic agent for such conditions. The proteins are also useful for

CC detecting endothelial damage or activation, detecting a tumour or tumour

CC neovasculature, cardiac disease, or endometriosis by detecting the amount

CC of ECSM4 present in a sample. The polynucleotide sequences encoding ECSM4

CC are useful in gene therapy for treating a hypoxic condition such as

CC cancer, cardiac disease, endometriosis or atherosclerosis and in the

CC manufacture of medicaments for treating the above disease. The sequences

CC are useful for modulating angiogenesis in an individual. The present

CC sequence represents a RT-PCR primer for RNA encoding human fatty acid

CC binding protein 4

XX

SQ Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 3.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 CAGTGTGAATGGGATGTA 210
 |||||
 DB 20 CAGTGTGAATGGGATGTA 1

RESULT 24

ABK87127
 ID ABK87127 standard; DNA; 20 BP.

AC
 XX

AC
 XX

DT 07-OCT-2002 (first entry)

DE Human fatty acid binding protein 4, RT-PCR primer #1.

XX Human; endothelial cell-specific molecule 4; ECSM4; neovasculture;
 KW imaging vascular endothelium; proliferative disease; cancer; psoriasis;
 KW diabetic retinopathy; atherosclerosis; menorrhagia; endothelial damage;
 KW tumour neovasculture; cardiac disease; endometriosis; hypoxic condition;
 KW angiogenesis; cytoskeletal; RT-PCR; fatty acid binding protein 4;
 KW reverse transcription-PCR; primer; ss.

XX Homo sapiens.

OS WO200236771-A2.

PN 10-MAY-2002.

PD 06-NOV-2001; 2001WO-GB004906.

PF 06-NOV-2000; 2000US-0245566P.

PR 07-MAR-2001; 2001US-0273662P.

XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY LTD.

PA Bicknell R, Huminiecki L;

PI WPI; 2002-508120/54.

DR Novel endothelial cell-specific molecule polypeptide 1 or 4, useful for

PT imaging, diagnosing and treating a condition involving vascular

PT endothelium e.g. cancer, cardiac disease, endometriosis, diabetes.

XX Example 1; Page 165; 248pp; English.

PS The present invention relates to endothelial cell-specific molecule 4
 XX (ECSM4), and the polynucleotide sequences encoding it. The ECSM4 proteins
 CC are useful for imaging vascular endothelium in the body of an individual,
 CC and for diagnosing and treating a proliferative disease or condition
 CC involving the vascular endothelium (preferably, neovasculture) such as
 CC cancer, psoriasis, diabetic retinopathy, atherosclerosis or menorrhagia.
 CC The ECSM4 proteins are also useful in the manufacture of diagnostic or
 CC prognostic agent for such conditions. The proteins are also useful for
 CC detecting endothelial damage or activation, detecting a tumour or tumour
 CC neovasculture, cardiac disease, or endometriosis by detecting the amount
 CC of ECSM4 present in a sample. The polynucleotide sequences encoding ECSM4
 CC are useful in gene therapy for treating a hypoxic condition such as
 CC cancer, cardiac disease, endometriosis or atherosclerosis and in the
 CC manufacture of medicaments for treating the above disease. The sequences
 CC are useful for modulating angiogenesis in an individual. The present
 CC sequence represents a RT-PCR primer for RNA encoding human fatty acid
 CC binding protein 4

XX Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match

Best Local Similarity 3.2%; Score 20; DB 1; Length 20;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 TGCAGCTTCCTTCTCACCTT 35
 |||||
 DB 1 TGCAGCTTCCTTCTCACCTT 20

RESULT 25

AAD29732
 ID AAD29732 standard; DNA; 20 BP.

XX
 AC

XX
 AC

DT 17-MAY-2002 (first entry)

DE aFABP cDNA amplifying forward PCR primer.

XX Pre-adipose cell line; white adipocyte; food ingredient; obesity; lipid;
 KW diabetes; cardiovascular disease; fatty acid binding protein; aFABP;
 KW PCR primer; ss.

XX Unidentified.

XX WO200206450-A1.

PN 24-JAN-2002.

PD 13-JUL-2001; 2001WO-EP008165.

PP 18-JUL-2000; 2000EP-00115489.

XX (NEST) SOC PROD NESTLE SA.

PA Darimont C, Mace K, Pfeifer A;

PI WPI; 2002-188539/24.

DR New human pre-adipose cell line capable of differentiating to adipose

XX cells, useful in developing drug, food ingredients, and supplements

PT against obesity, diabetes and cardiovascular diseases.

XX Example 5; Page 11; 30pp; English.

PS The present invention relates to new human pre-adipose cell lines capable

XX to differentiate to white adipose cells, exhibiting essentially the same

CC cellular properties of normal white adipose cells. The human pre-adipose

CC cell lines are useful for the identification of substances controlling

CC the regulation of lipid uptake and release by human white adipocytes, and

CC substances controlling the differentiation of preadipocytes into mature

CC adipocytes. They are useful for screening compounds capable to regulate

CC the secretion of any metabolites or hormones from human white adipocytes.

CC Sequences of the invention are useful for developing drugs, food

CC ingredients and supplements against obesity, diabetes and cardio-

CC vascular diseases. The present DNA sequence is a PCR primer which is used

CC for amplifying fatty acid binding protein (aFABP) encoding cDNA. This

CC primer is used in the exemplification of the invention for the expression

CC of adipocytes in differentiated immortalised human preadipose cells

XX Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match

Best Local Similarity 3.2%; Score 20; DB 1; Length 20;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 GGTACCTGGAACTTGTCTC 100
 |||||
 DB 1 GGTACCTGGAACTTGTCTC 20

RESULT 26

AAD29733/G

ID AAD29733 standard; DNA; 20 BP.

XX
 AC

XX
 AC

XX AAD29733;

XX

DT 17-MAY-2002 (first entry)
 XX afABP cDNA amplifying reverse PCR primer.
 DE
 XX Pre-adipose cell line; white adipocyte; food ingredient; obesity; lipid;
 KW diabetes; cardiovascular disease; fatty acid binding protein; afABP;
 KW PCR primer; ss.
 XX Unidentified.
 OS
 XX WO200206450-A1.
 PN
 XX 24-JAN-2002.
 PD
 XX 13-JUL-2001; 2001WO-EP008165.
 DF
 XX 18-JUL-2000; 2000EP-00115489.
 PR
 XX (NEST) SOC PROD NESTLE SA.
 PA
 XX Darimont C, Mace K, Pfeifer A;
 PI
 XX WPI; 2002-198539/24.
 DR
 XX New human pre-adipose cell line capable of differentiating to adipose
 XX cells, useful in developing drug, food ingredients, and supplements
 PT against obesity, diabetes and cardiovascular diseases.
 PT
 XX Example 5; Page 11; 30pp; English.
 PS
 XX The present invention relates to new human pre-adipose cell lines capable
 XX to differentiate to white adipose cells, exhibiting essentially the same
 XX cellular properties of normal white adipose cells. The human pre-adipose
 CC cell lines are useful for the identification of substances controlling
 CC the regulation of lipid uptake and release by human white adipocytes, and
 CC substances controlling the differentiation of preadipocytes into mature
 CC adipocytes. They are useful for screening compounds capable to regulate
 CC the secretion of any metabolites or hormones from human white adipocytes.
 CC Sequences of the invention are useful for developing drugs, food
 CC ingredients and supplements against obesity, diabetes and cardio-
 CC vascular diseases. The present DNA sequence is a PCR primer which is used
 CC for amplifying fatty acid binding protein (afABP) encoding cDNA. This
 CC primer is used in the exemplification of the invention for the expression
 CC of adipocytes in differentiated immortalised human preadipose cells
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 3.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 471 CGTTCACCTGGACTGAAGTT 490
 Db 20 CGTTCACCTGGACTGAAGTT 1
 RESULT 27
 AAD55891/c
 ID AAD55891 standard; DNA; 20 BP.
 AC
 AC AAD55891;
 XX
 DT 07-AUG-2003 (first entry)
 DE Human ap2 gene amplifying forward RT-PCR primer.
 DE
 XX Adipose-derived stem cell; ADSC; transgene; cell therapy; gene therapy;
 KW primer; reverse transcription; RT; PCR; ap2; human; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO2003022988-A2.
 PN
 XX

PD 20-MAR-2003.
 XX 31-JUL-2002; 2002WO-US024374.
 PF
 XX 10-SEP-2001; 2001US-00952522.
 PR
 XX (REGC) UNIV CALIFORNIA.
 PA
 XX Hedrick MH, Katz AJ, Lull R, Futrell JW, Benhaim P, Lorenz HP;
 PI Zhu M;
 PI
 XX WPI; 2003-354531/33.
 DR
 XX New isolated adipose-derived stem cell, useful for generating
 PT differentiated tissues and structures both in vivo and in vitro or
 PT providing conditioned culture media to support the growth and expansion
 PT of other cell populations.
 PT
 XX Example 11; Page 234; 241pp; English.
 PS
 XX The invention relates to adipose-derived stem cells (ADSC) and lattices
 CC which are useful for generating differentiated tissues and structures
 CC both in vivo and in vitro, for producing molecules such as hormones and
 CC for providing a conditioned culture media for supporting the growth and
 CC expansion of other cell populations. Lattices are useful as substrates
 CC for facilitating the growth and differentiation of cells into mature
 CC tissues or structures. The invention is useful for delivering a transgene
 CC to an animal. The invention is also useful in cell therapy and gene
 CC therapy. The present sequence is reverse transcription PCR (RT-PCR)
 CC primer used to amplify human ap2 gene. This sequence is used in the
 CC exemplification of the invention
 CC
 SQ Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 3.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 353 ATGGGATGGAAATCAACCA 372
 Db 20 ATGGGATGGAAATCAACCA 1
 RESULT 28
 AAI66789/c
 ID AAI66789 standard; DNA; 19 BP.
 AC
 AC AAI66789;
 XX
 DT 07-JAN-2002 (first entry)
 XX
 DE ap2 mRNA amplifying RT-PCR primer R.
 DE
 XX Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;
 KW Ihh; sonic hedgehog; Shh; therapeutic; cyrostatic; primer; RT-PCR; ss.
 KW
 XX Synthetic.
 OS
 XX WO200164238-A2.
 DN
 XX 07-SEP-2001.
 PD
 XX 28-FEB-2001; 2001WO-US006450.
 PF
 XX 29-FEB-2000; 2000US-0186058P.
 PR
 XX (CURI-) CURIS INC.
 PA
 XX Zehentner B, Leser-Reiff U, Burtscher H;
 PI
 XX WPI; 2001-607352/69.
 DR
 XX Method for regulating formation and/or maintenance of adipocyte tissue by
 PT

PT contacting pre-adipocyte or adipocyte cells with a hedgehog polypeptide
 PT or ptc therapeutic.
 XX Example; Page 77; 132pp; English.

CC The invention provides a method for regulating formation and/or
 CC maintenance of adipocyte tissue that comprises contacting pre adipocyte
 CC or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The
 CC method is used for regulating the growth state of an adipocyte stem/
 CC progenitor cell, and treating or preventing disorders of, or surgical or
 CC cosmetic repair of, adipocyte tissues, e.g. for treating or preventing
 CC hyperplastic or neoplastic conditions affecting adipocyte tissue, such as
 CC soft tissue tumors, especially adipose cell tumors, e.g. lipomas,
 CC fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or
 CC liposarcomas. Hedgehog polypeptides can be used in combination with other
 CC therapeutic agents. Sequences AAI66784-793 represent primers used in
 CC quantitative RT-PCR of PPARgamma, ap2, gli, ptc and actin mRNAs, during
 CC the course of the invention

SQ Sequence 19 BP; 2 A; 7 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 3.0%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 27;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 347 GCAGAAATGGGATGGA AAA 365
 |||||
 DB 19 GCAGAAATGGGATGGA AAA 1

RESULT 29
 AAD25483/c
 ID AAD25483 standard; DNA; 19 BP.
 AC AAD25483;
 DT 26-MAR-2002 (first entry)

DE Probe #20 used in ap2 assay for antagonist.

XX Benzoxazinone derivative; glucose metabolism; lipid metabolism; NIDDM;
 KW PPAR gamma; peroxisome proliferator activated receptor gamma; therapy;
 KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; PCOS;
 KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
 KW ischaemia; obesity; heart disease; irritable bowel disorder; stroke;
 KW reduced insulin sensitivity; inflammation; cataract; ap2 mRNA; probe; ss.

OS Unidentified.
 OS WO200187860-A2.
 FN 22-NOV-2001.
 PF 11-MAY-2001; 2001WO-US015320.
 PR 12-MAY-2000; 2000US-0203859P.
 PR 11-MAY-2001; 2001US-00853798.
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX Burris TP, Rybczynski PJ;
 XX WPI; 2002-082970/11.
 XX Use of benzoxazinone derivatives for treating a subject suffering from a
 PT disorder in glucose and lipid metabolism such as non-insulin dependant
 PT diabetes mellitus or obesity.

XX Example 2; Page 34; 45pp; English.

XX The invention relates to benzoxazinone derivatives useful as peroxisome
 CC proliferator activated receptor (PPAR) gamma modulators. The invention
 CC also relates to pharmaceutical compositions comprising benzoxazinone

CC derivatives and methods for treating the onset of a disorder in glucose
 CC and lipid metabolism, preferably a condition of reduced insulin
 CC sensitivity such as non-insulin dependant diabetes mellitus (NIDDM),
 CC obesity, nephropathy, neuropathy, retinopathy, atherosclerosis,
 CC polycystic ovary syndrome (PCOS), hypertension, ischaemia, stroke, heart
 CC diseases, irritable bowel disorder, inflammation and cataract. The
 CC present sequence is a probe designed to anneal to the ap2 mRNA and
 CC function in the bDNA mRNA detection system. This probe used in the ap2
 CC assay for antagonist which is used in the exemplification of the
 CC invention

XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 3.0%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 27;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACTT 435
 |||||
 DB 19 GTCATGAAGGCGTCACTT 1

RESULT 30
 AAI68023/c
 ID AAI68023 standard; DNA; 19 BP.
 AC AAI68023;
 DT 13-MAR-2002 (first entry)

XX ap2 mRNA specific oligonucleotide probe.

DE Peroxisome proliferator activated receptor gamma; benzoxazinone; NIDDM;
 KW non-insulin dependant diabetes mellitus; antidiabetic; anorectic;
 KW nephrotropic; ophthalmological; antiarteriosclerotic; cytostatic;
 KW hypotensive; vasotropic; cerebroprotective; cardiant; antiinflammatory;
 KW PPARgamma; probe; ap2; ss.

OS Synthetic.
 OS WO200187861-A2.
 FN 22-NOV-2001.
 PF 11-MAY-2001; 2001WO-US015377.
 PR 12-MAY-2000; 2000US-0203861P.
 PR 11-MAY-2001; 2001US-00854368.
 PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX Burris TP, Demarest KT, Combs DW, Rybczynski PJ, Turchi IJ;
 XX WPI; 2002-082971/11.
 XX Use of benzoxazinone derivatives for treating a subject suffering from a
 PT condition associated with peroxisome proliferator activated receptor
 PT gamma activity e.g. non-insulin dependant diabetes mellitus and obesity.

XX Example 7; Page 29; 46pp; English.

XX The invention provides methods of treating a subject suffering from a
 CC condition associated with peroxisome proliferator activated receptor
 CC gamma (PPARGamma) activity that involves administering a benzoxazinone
 CC compound of a specified formula to the subject. The method is useful for
 CC treating and inhibiting in a subject the onset of a condition associated
 CC with PPARgamma activity such as a condition of reduced insulin
 CC sensitivity, non-insulin dependant diabetes mellitus, obesity,
 CC nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovary
 CC syndrome, hypertension, ischemia, stroke, heart diseases, irritable bowel
 CC disorder, inflammation and cataract. Sequences AAI68004-023 represent
 CC oligonucleotide probes specific for ap2 used in ap2 mRNA assay for
 CC antagonists

XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACCTT 435
DB 19 GTCATGAAGGCGTCACCTT 1

RESULT 31
AAD24707/c
ID AAD24707 standard; DNA; 19 BP.

XX AC AAD24707;
XX DT 12-MAR-2002 (first entry)
XX DE Probe #20, used in ap2 assay for antagonist.

XX 4h-Benzo(1,4)oxazin-3-one compound; glucose metabolism; lipid metabolism;
KW PPAR gamma; peroxisome proliferator activated receptor; therapy; NIDDM;
KW non-insulin dependant diabetes mellitus; nephropathy; neuropathy; stroke;
KW atherosclerosis; retinopathy; polycystic ovary syndrome; hypertension;
KW ischaemia; obesity; heart disease; irritable bowel disorder; cataract;
KW anorectic; nephrotropic; ophthalmological; cytostatic; hypertensive;
KW vasotropic; cerebroprotective; cardiatic; antiinflammatory; probe;
KW ap2 mRNA; ss.

XX OS Unidentified.
XX PN WO200187862-A2.
XX PD 22-NOV-2001.
XX PF 11-MAY-2001; 2001WO-US015383.
XX PR 12-MAY-2000; 2000US-0203860P.
XX PR 11-MAY-2001; 2001US-00854302.
XX PA (ORTH) ORTHO-MCNEIL PHARM INC.
XX PI Burris TP, Combs DW, Rybczynski PJ;
XX DR WPI; 2002-055671/07.
XX PT Use of 4h-benzo(1,4)oxazin-3-one derivatives for treating a subject
PT suffering from a disorder in glucose and lipid metabolism e.g. non-
PT insulin dependant diabetes mellitus and obesity.
XX PS Example 38; Page 59; 76pp; English.

XX The patent discloses 4h-Benzo(1,4)oxazin-3-one compounds which are useful
CC as peroxisome proliferator activated receptor (PPAR) gamma agonists and
CC antagonists. The invention also relates to compositions comprising such
CC compounds and methods for treating or inhibiting the onset of a disorder
CC in glucose and lipid metabolism, preferably a condition of reduced
CC insulin sensitivity, such as non-insulin dependent diabetes mellitus
CC (NIDDM), obesity, atherosclerosis, nephropathy, neuropathy, retinopathy,
CC polycystic ovary syndrome, hypertension, ischaemia, stroke, heart
CC diseases, irritable bowel disorder, inflammation and cataract. The
CC present DNA sequence is a probe which is designed to anneal to ap2 mRNA
CC and function in the bDNA mRNA detection system. This probe is used in ap2
CC assay for antagonist in the exemplification of the invention

XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACCTT 435
DB 19 GTCATGAAGGCGTCACCTT 1

RESULT 32
AAD55892
ID AAD55892 standard; DNA; 20 BP.

XX AC AAD55892;
XX DT 07-AUG-2003 (first entry)
XX DE Human ap2 gene amplifying reverse RT-PCR primer #1.
XX KW Adipose-derived stem cell; ADSC; transgene; cell therapy; gene therapy;
KW primer; reverse transcription; RT; PCR; ap2; human; ss.
XX OS Homo sapiens.
XX PN WO2003022988-A2.
XX PD 20-MAR-2003.
XX PF 31-JUL-2002; 2002WO-US024374.
XX PR 10-SEP-2001; 2001US-00952522.
XX PA (REGC) UNIV CALIFORNIA.
XX PI Hedrick ME, Katz AJ, Lull R, Futrell JW, Benhaim P, Lorenz HP;
PI Zhu M;
XX DR WPI; 2003-354531/33.
XX PT New isolated adipose-derived stem cell, useful for generating
PT differentiated tissues and structures both in vivo and in vitro or
PT providing conditioned culture media to support the growth and expansion
PT of other cell populations.
XX PS Example 11; Page 234; 241pp; English.

XX The invention relates to adipose-derived stem cells (ADSC) and lattices
CC which are useful for generating differentiated tissues and structures
CC both in vivo and in vitro, for producing molecules such as hormones and
CC for providing a conditioned culture media for supporting the growth and
CC expansion of other cell populations. Lattices are useful as substrates
CC for facilitating the growth and differentiation of cells into mature
CC tissues or structures. The invention is useful for delivering a transgene
CC to an animal. The invention is also useful in cell therapy and gene
CC therapy. The present sequence is reverse transcription PCR (RT-PCR)
CC primer used to amplify human ap2 gene. This sequence is used in the
CC exemplification of the invention

XX SQ Sequence 20 BP; 5 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 3.0%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 259 TACTGGGCCAGGAATTGA 277
DB 1 TACTGGGCCAGGAATTGA 19

RESULT 33
AA32484/c
ID AA32484 standard; DNA; 22 BP.

XX AC AA32484;
XX DT 22-JUN-1999 (first entry)
XX

DE Forward primer flanking CA repeat in porcine A-FABP gene.
 XX A-FABP; adipocyte fatty acid binding protein; pig; porcine; allele;
 KW breeding program; fatty acid transport; fat deposition; primer; ss.
 XX Synthetic.
 OS Sus scrofa.
 XX WO9914365-A1.
 PN 25-MAR-1999.
 PD 18-SEP-1998; 98WO-NL000541.
 XX 18-SEP-1997; 97EP-00202857.
 PR (DALL-) DALLAND BV.
 PA (PROV-) PROVA BV.
 PA (STAM-) STAMBOEK ZUID BV.
 PA (NNEV-) NOORD NEDERLANDS VARKENSTAMBOEK BV.
 PA (DIER-) STICHTING INST DIERHOUDERIJ EN DIERGEZON.
 XX Gerbens F;
 PI WPI; 1999-229550/19.
 DR Nucleic acid specific for the pig adipocyte fatty acid binding protein.
 XX Disclosure; Fig 4; 36pp; English.
 PS The invention relates to a gene encoding pig A-FABP (adipocyte fatty acid
 CC binding protein). Nucleic acid specific for the A-FABP gene or its
 CC fragments are used (1) to localize, identify or mark alleles in the gene,
 CC particularly those associated with production traits in pigs; and (2) for
 CC specific amplification of fragments, its alleles or trait loci,
 CC particularly for distinguishing between alleles. Pigs carrying particular
 CC alleles are selected for use in breeding programs. Since A-FABP is
 CC involved in fatty acid transport and fat deposition, and may control
 CC insulin dependency, selection of particular alleles may allow regulation
 CC of fat deposition in muscle; body weight, weight gain and feed efficiency
 CC ; fatty acid content of meat; embryo survival; birth rate and litter
 CC size, and milk quality and quantity
 XX Sequence 22 BP; 4 A; 3 C; 6 G; 9 T; 0 U; 0 Other;
 SQ Query Match 3.0%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 20.9%; Pred. No. 32;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 212 CACCATTAAATCTGAAAGTACC 233
 DB 22 CACCATTAGATCAGAAAGTACC 1
 RESULT 34
 AAD48760
 ID AAD48760 standard; RNA; 18 BP.
 AC AAD48760;
 XX 07-MAR-2003 (first entry)
 DT Human fatty acid binding protein 2 (FABP-2) RNA fragment #2.
 DE Human; RNA binding molecule; fatty acid binding protein 2; FABP-2; ss.
 KW Human; RNA binding molecule; fatty acid binding protein 2; FABP-2; ss.
 XX Homo sapiens.
 OS WO200281748-A1.
 PN 17-OCT-2002.
 PD 04-APR-2002; 2002WO-SE000677.
 PF

XX 05-APR-2001; 2001SE-00001218.
 PR 05-APR-2001; 2001US-0281384p.
 XX (BIOV-) BIOVITRUM AB.
 PA Ekblom J;
 PI WPI; 2003-058568/05.
 DR Identifying RNA-binding molecule by predicting structure of RNA fragment,
 PT synthesizing DNA fragment corresponding to predicted RNA structure,
 PT performing reporter gene assay after placing the DNA upstream of reporter
 PT gene.
 XX Claim 10; Page 28; 35pp; English.
 PS The present invention relates to a method of identifying RNA-binding
 CC molecule comprising predicting the structure of RNA-fragment, selecting a
 CC suitable predicted RNA fragment with an individual stem, synthesizing a
 CC DNA-fragment corresponding to the RNA fragment, inserting the DNA
 CC fragment in upstream proximity of reporter assay gene to form reporter
 CC construct and performing a reporter gene assay which detects interaction
 CC between a molecule to be tested for RNA-binding and RNA fragment of the
 CC reporter construct. The method is useful for identifying an RNA binding
 CC molecule. The present sequence is human fatty acid binding protein 2
 CC (FABP-2) RNA fragment. This sequence is used to illustrate the method of
 CC the invention
 XX Sequence 18 BP; 3 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
 SQ Query Match 2.8%; Score 18; DB 1; Length 18;
 Best Local Similarity 77.8%; Pred. No. 30;
 Matches 14; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 OY 9 AGGAGGGTGCAGCTTCCT 26
 DB 1 AGGAGGGGCGAGCUUCU 18
 RESULT 35
 ABZ85335
 ID ABZ85335 standard; DNA; 20 BP.
 AC ABZ85335;
 XX 17-OCT-2003 (first entry)
 DT Human oligonucleotide sequence.
 DE Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013135.
 XX 24-APR-2001; 2001US-0286137P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR

XX PN WO200297114-A2.
 XX PD 05-DEC-2002.
 XX PF 29-MAY-2002; 2002WO-US016840.
 XX PR 29-MAY-2001; 2001US-0294140P.
 XX PR 06-JUN-2001; 2001US-0296249P.
 XX PR 10-SEP-2001; 2001US-0318471P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Mcswiggen J;
 XX DR WPI; 2003-140484/13.
 XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX PS Claim 58; Page 120; 185pp; English.
 XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,
 CC AB266530 - AB266595 represent substrate/target sequences for the human
 CC ribozymes of the invention
 XX SQ Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 40;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 8 CAGGAGGGTGCAGCTTC 24
 |||||
 Db 17 CAGGAGGGTTCAGCTTC 1
 RESULT 38
 AAZ77088
 ID AAZ77088 standard; DNA; 18 BP.
 AC AAZ77088;
 XX DT 10-SEP-2001 (first entry)
 XX DE Human biallelic marker downstream amplification primer SEQ ID NO:11444.
 XX KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX OS Homo sapiens.
 XX PN WO9954500-A2.
 XX PD 28-OCT-1999.
 XX PF 21-APR-1999; 99WO-IB000822.
 XX PR 21-APR-1998; 98US-0082614P.
 XX PR 23-NOV-1998; 98US-0109732P.
 XX PA (GEST) GENSET.
 XX PI Cohen D, Blumenfeld M, Chumakov I;
 XX DR WPI; 2000-013267/01.
 XX PT Novel biallelic markers used to construct a high density disequilibrium

XX (GEST) GENSET.
 XX PI Cohen D, Blumenfeld M, Chumakov I;
 XX DR WPI; 2000-013267/01.
 XX PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX PS Claim 9; Page 2670; 2745pp; English.
 XX CC AA265654 to AA269578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA269579 to AA277440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 2.4%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 42;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 570 ATTTTCTCCCAAGCTGA 586
 |||||
 Db 1 ATTTTCTCCCAAGCTGA 17
 RESULT 39
 AAZ73388
 ID AAZ73388 standard; DNA; 18 BP.
 AC AAZ73388;
 XX DT 10-SEP-2001 (first entry)
 XX DE Human biallelic marker upstream amplification primer SEQ ID NO:7744.
 XX KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX OS Homo sapiens.
 XX PN WO9954500-A2.
 XX PD 28-OCT-1999.
 XX PF 21-APR-1999; 99WO-IB000822.
 XX PR 21-APR-1998; 98US-0082614P.
 XX PR 23-NOV-1998; 98US-0109732P.
 XX PA (GEST) GENSET.
 XX PI Cohen D, Blumenfeld M, Chumakov I;
 XX DR WPI; 2000-013267/01.
 XX PT Novel biallelic markers used to construct a high density disequilibrium

```

PT map of the human genome.
XX
PS Claim 9; Page 1882; 2745pp; English.
XX
CC AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 18 BP; 9 A; 4 C; 5 G; 0 T; 0 U; 0 Other;

  Query Match      2.3%; Score 14.8; DB 1; Length 18;
  Best Local Similarity 88.9%; Pred. No. 45;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 450 GAGAGACGATAGCCCAAG 467
Db 1 GAGAGAGCAAAACCCCAAG 18

RESULT 40
AAD33908
ID AAD33908 standard; DNA; 18 BP.
AC AAD33908;
XX
XX 16-JUL-2002 (first entry)
XX
XX Human carboxypeptidase-like enzyme DNA amplifying PCR forward primer.
XX
XX Human; carboxypeptidase-like enzyme; therapy; cancer; asthma; allergy;
XX chronic obstructive pulmonary disease; cytostatic; antiasthmatic;
XX antiallergic; enzyme; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX WO200220805-A2.
XX
XX 14-MAR-2002.
XX
XX 05-SEP-2001; 2001WO-EP010203.
XX
XX 11-SEP-2000; 2000US-0231546P.
XX
XX (FARB ) BAYER AG.
XX
XX Liou J;
XX
XX WPI; 2002-315660/35.
XX
XX New purified human carboxypeptidase-like enzyme, useful for identifying
XX modulators of enzyme activity for treating cancer, asthma, allergy or
XX chronic obstructive pulmonary disease.
XX
XX Example 6; Page 68; 127pp; English.
XX
XX The invention relates to a purified human carboxypeptidase-like enzyme.
XX The enzyme is useful for screening for agents which decrease the activity
XX of an carboxypeptidase-like enzyme. The invention is also useful for
XX treating a carboxypeptidase-like enzyme dysfunction related diseases
XX condition such as chronic obstructive pulmonary disease, cancer, asthma
XX or allergy. The invention is also useful for modulating carboxypeptidase-
XX

```

```

CC like enzyme activity in a disease condition. The invention is useful in
CC diagnostic assays for detecting diseases and abnormalities or
CC susceptibility to diseases and abnormalities related to presence of
CC mutations in the nucleic acid sequences which encode the enzyme. The
CC present sequence is a PCR primer used for amplifying human DNA encoding
CC carboxypeptidase-like enzyme
XX
SQ Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match      2.3%; Score 14.8; DB 1; Length 18;
  Best Local Similarity 88.9%; Pred. No. 45;
  Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 151 CCAGAAAGTGGCTGGCA 168
Db 1 CCAGGAGGTGGTTGGCA 18

RESULT 41
AAQ11390
ID AAQ11390 standard; DNA; 17 BP.
XX
XX AAQ11390;
XX
XX 25-MAR-2003 (revised)
XX 02-JUL-1991 (first entry)
XX
XX Probe COD 957 specific for T. hyo 39kD antigen genes.
XX
XX Swine dysentery; vaccine.
XX
XX Synthetic.
XX
XX WO9104036-A.
XX
XX 04-APR-1991.
XX
XX 13-SEP-1989; 89US-00406535.
XX
XX 13-SEP-1989; 89US-00406535.
XX
XX (MLTB-) ML TECHN VENTURES.
XX
XX Gabe J, Dragon E, Mccaman M;
XX
XX WPI; 1991-117317/16.
XX
XX Treponema hyodysenteriae antigens - having molecular wt. of 39 K daltons
XX and their DNA codes, and use for preparing vaccine.
XX
XX Disclosure; Page 38; 84pp; English.
XX
XX The probe was designed from the sequence of the pTrep106 encoding the T.
XX hyo 39 kD antigen no. 1. It was used for screening of clones prepd. from
XX T. hyo genomic DNA following PCR treatment. See also AAQ11377-Q11409.
XX
XX (Updated on 25-MAR-2003 to correct PA field.)
XX
XX Sequence 17 BP; 6 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match      2.3%; Score 14.4; DB 1; Length 17;
  Best Local Similarity 93.8%; Pred. No. 45;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 223 CTGAAAGTACCTTTAA 238
Db 1 CCGAAAGTACCTTTAA 16

RESULT 42
ABV80082
ID ABV80082 standard; DNA; 17 BP.
XX
XX ABV80082;
AC ABV80082;

```

```

XX DT 03-JAN-2003 (first entry)
XX AC
XX DT
XX DE
XX DE
XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX KW human testis expressed Patched like protein; testis; adrenal; liver;
XX KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS
XX XX Homo sapiens.
XX PN EP1229046-A2.
XX PD
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI
XX PI Zhan J;
XX DR WPI; 2002-676582/73.
XX DR
XX PT Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 237; 718pp; English.
XX PS
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 45;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 58 ACAAAATGCTGTATGC 73
XX | | | | | | | | | |
XX Db 2 ACAAAATGCTGTATGC 17
XX
XX RESULT 43
XX ABV80083
XX ID ABV80083 standard; DNA; 17 BP.

```

```

XX AC
XX DT
XX DE
XX DE
XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX KW human testis expressed Patched like protein; testis; adrenal; liver;
XX KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS
XX XX Homo sapiens.
XX PN EP1229046-A2.
XX PD
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI
XX PI Zhan J;
XX DR WPI; 2002-676582/73.
XX DR
XX PT Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 238; 718pp; English.
XX PS
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 45;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 58 ACAAAATGCTGTATGC 73
XX | | | | | | | | | |
XX Db 1 ACAAAATGCTGTATGC 16
XX
XX RESULT 44

```

ABK17807/C	
ID	ABK17807 standard; RNA; 17 BP.
XX	
AC	ABK17807;
XX	
DT	09-APR-2002 (first entry)
XX	
DE	Human ERG hammerhead ribozyme target sequence, Seq ID No 454.
XX	
KW	Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW	ophthalmological; antiarthritic; antiposrotic; virucide; osteopathic;
KW	vulnervary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW	tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW	neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW	angiobroma of tuberos sclerositis; port-wine stain; wound healing;
KW	Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukemia; ss;
KW	amberzyme.
XX	
OS	Homo sapiens.
XX	
EN	WO200108124-A2.
XX	
PD	22-NOV-2001.
XX	
PF	16-MAY-2001; 2001WO-US015866.
XX	
PR	16-MAY-2000; 2000US-00572021.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(GLAX) GLAXO GROUP LTD.
XX	
PI	Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX	
DR	WPI; 2002-082995/11.
XX	
PT	Novel polynucleotide which down regulates expression of Ets-related gene,
PT	useful for treating cancer, diabetic retinopathy, macular degeneration,
PT	arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX	
PS	Claim 4; Page 67; 149pp; English.
XX	
CC	The invention relates to a nucleic acid molecule (I) which down regulates
CC	expression of an Ets-related gene (ERG). (I) is useful for treating
CC	conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC	tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC	neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC	vulgaris, angiobroma of tuberos sclerositis, port-wine stains, Sturge
CC	Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC	syndrome, leukemia, osteoporosis and wound healing. (I) is useful for
CC	treating a patient having a condition associated with the level of ERG,
CC	by contacting cells of the patient with (I) under conditions suitable for
CC	the treatment. The method comprises the use of one or more therapies
CC	under conditions suitable for the treatment. Leukemia or tumour
CC	angiogenesis is treated by administering (I) to the patient in
CC	conjunction with one or more of other therapies such as radiation or
CC	chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC	cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC	ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC	cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC	diseases related to the expression of ERG, and as diagnostic tool to
CC	examine genetic drift and mutations within diseased cells or to detect
CC	the presence of ERG RNA in a cell. (I) is useful for specifically
CC	targeting genes that share homology with ERG gene or ERG fusion genes.
CC	ABK17354-ABK22719 represent nucleic acids, including antisense and
CC	enzymatic nucleic acid molecules which regulate expression of ERG, and
CC	related PCR primers of the invention
XX	
SQ	Sequence 17 BP; 8 A; 2 C; 3 G; 0 T; 4 U; 0 Other;

```

RESULT 46
AAS95047
ID AAS95047 standard; DNA; 18 BP.
XX
XX
AC AAS95047;
XX
DT 13-FEB-2002 (first entry)
XX
DE Human otoferlin exon PCR primer #12.
XX
DE Human; mouse; otoferlin; OTOF; brain; auditory function; PCR primer;
KW autosomal nonsyndromic prelingual deafness; DFNB9; ss.
XX
OS Homo sapiens.
XX
FN WO200170972-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-IB000578.
XX
PR 24-MAR-2000; 2000US-0191738P.
XX
PA (INSP ) INST PASTEUR.
PA (CNRS ) CNRS CENT NAT RECH SCI.
XX
PI Yasunaga S, Grati M, Cohen-Salmon M, El Amraoui A, Petit C;
PI Weil D;
XX
DR WPI; 2001-611499/70.
XX
PT Novel human gene Otoferlin, underlying an autosomal recessive
PT nonsyndromic prelingual deafness, DFNB9, and proteins encoded by the
PT gene, implicated in deafness.
XX
PS Claim 25; Page 17; 99pp; English.
XX
CC The invention relates to a purified polynucleotide (I) encoding a protein
CC sequence (II) encoded by a novel human gene, otoferlin (OTOF) or the long
CC human otoferlin isoform in brain. (I) was identified as underlying an
CC autosomal nonsyndromic prelingual deafness DFNB9, and is thus useful for
CC detecting deafness disease in humans and for characterising the functions
CC of proteins and genes encoding them in auditory function. AAS95022-
CC AAS95248 represent human and mouse otoferlin coding sequences, PCR
CC primers and related sequences of the invention
XX
SQ Sequence 18 BP; 2 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 47;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 333 GTCCTGGTACATGTGC 348
DB 1 GGCCTGGTACATGTGC 16

RESULT 47
ADB42764/c
ID ADB42764 standard; DNA; 17 BP.
XX
XX
AC ADB42764;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3087.
XX
KW cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

diagnosis.
KW
XX Homo sapiens.
XX
PN WO2003040369-A2.
XX
XX 15-MAY-2003.
XX
XX 17-SEP-2002; 2002WO-IB004219.
XX
XX 17-SEP-2001; 2001PR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Anson R, Tuijnder M;
XX
XX WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
XX polypeptide and antibodies.
XX
XX Disclosure; Page 392; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 346 TGCAGAAATGGGAT 359
DB 15 TGCAGAAATGGGAT 2

RESULT 48
AAA21306
ID AAA21306 standard; RNA; 17 BP.
XX
XX AAA21306;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4532.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIB-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophtalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;

```

KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

OS Homo sapiens.

XX XX WO9950403-A2.

XX PD 07-OCT-1999.

XX PF 24-MAR-1999; 99WO-US006507.

XX PR 27-MAR-1998; 98US-0079678P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;

XX DR WPI; 1999-591315/50.

XX PT Novel ribozymes for modulating the synthesis, expression and/or stability

XX PT of an mRNA encoding an angiogenic factors.

XX PS Claim 55; Page 200; 305pp; English.

XX XX The present invention describes enzymatic cleave RNA molecules with RNA

CC cleaving activity, which specifically cleave RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

CC corresponding target sequences; AAA17623 to AAA17684 represent their

CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18385 to AAA19086

CC and AAA19155 to AAA19222 represent their corresponding target sequences;

CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

CC AAA21596 to AAA21688 represent their corresponding target sequences;

CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence

CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

CC AAA23422 represent their corresponding target sequences. The ribozymes of

CC the invention are used for modulating the synthesis, expression and/or

CC stability of an mRNA encoding angiogenic factor, especially ARNT.

CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

CC especially used to treat cancer, diabetic retinopathy, age related

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

CC and other syndromes and diseases related to the levels of ARNT, Tie-2,

CC integrin subunit alpha-6, or integrin subunit beta-3

XX XX Sequence 17 BP; 4 A; 1 C; 2 G; 0 T; 10 U; 0 Other;

SQ Query Match 2.2%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. NO. 49;

Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 581 AGCTGATTTTATTCAT 597

DB 1 ACUGUGAUUUUUUUUAU 17

RESULT 49

AAA21305

ID AAA21305 standard; RNA; 17 BP.

XX AAA21305;

XX 19-JUN-2000 (first entry)

XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4531.

XX Human; aryl hydrocarbon nuclear transporter; ARNT; Tie-2; angiogenesis;

XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;

KW

KW

KW

KW

KW

KW

KW

KW

OS

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 ophthalmologic; antiinflammatory; antiarthritis; antipsoriatic; ARMD;
 dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 age related macular degeneration; inflammation; neovascular glaucoma;
 myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

Homo sapiens.

WO9950403-A2.

07-OCT-1999.

24-MAR-1999; 99WO-US006507.

27-MAR-1998; 98US-0079678P.

(RIBO-) RIBOZYME PHARM INC.

Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;

WPI; 1999-591315/50.

Novel ribozymes for modulating the synthesis, expression and/or stability

of an mRNA encoding an angiogenic factors.

Claim 55; Page 200; 305pp; English.

The present invention describes enzymatic cleave RNA molecules with RNA

cleaving activity, which specifically cleave RNA encoded by an aryl

hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

corresponding target sequences; AAA17623 to AAA17684 represent their

AAA19154 represent ribozyme sequences for Tie-2, and AAA18385 to AAA19086

and AAA19155 to AAA19222 represent their corresponding target sequences;

AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

AAA21596 to AAA21688 represent their corresponding target sequences;

AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence

for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

AAA23422 represent their corresponding target sequences. The ribozymes of

the invention are used for modulating the synthesis, expression and/or

stability of an mRNA encoding angiogenic factor, especially ARNT,

integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

especially used to treat cancer, diabetic retinopathy, age related

neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

and other syndromes and diseases related to the levels of ARNT, Tie-2,

integrin subunit alpha-6, or integrin subunit beta-3

XX Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 49;

Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 580 AAGCTGATTTTATTCAA 596

DB 1 AAGCUGAUUUUUUUA 17

RESULT 50

AAAS05096/C

ID AAAS05096 standard; DNA; 17 BP.

XX AAAS05096;

XX 07-SEP-2001 (first entry)

XX Neurofibromatosis (NF1) HA PCR primer #16.
 XX
 DE Neurofibromatosis type 1; NF1; peripheral blood lymphocyte; PBL; EBV; ss;
 KW Epstein-Barr virus; B-lymphoblastoid cell; phytohaemagglutinin; PHA;
 KW frame shift mutation; mis-sense mutation; silent mutation; PCR primer;
 KW sequencing primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200129251-A2.
 XX
 PD 26-APR-2001.
 XX
 PF 18-OCT-2000; 2000WO-EP010255.
 XX
 PR 18-OCT-1999; 99EP-00870216.
 PR 05-JUN-2000; 2000EP-00870122.
 XX
 PA (UYGE-) UNIV GENT.
 XX
 PI Messiaen L, Callens T;
 XX
 DR WPI; 2001-300341/31.
 XX
 PT Mutation analysis of NF1 gene by treating EBV transformed lymphoblastoid
 PT cell lines formed with lymphocytes of patient with protein synthesis
 PT inhibitor, and obtaining peptides by translating amplified RNA from cell
 PT line.
 XX
 PS Claim 9; Page 70; 102pp; English.
 XX
 CC The sequences represent neurofibromatosis type 1 (NF1) cDNA fragments and
 CC PCR primers and sequencing primers for use in mutation analysis of NF1. A
 CC method for mutation analysis of the NF1 gene involves isolating
 CC peripheral blood lymphocytes (PBL) of a patient, establishing Epstein-
 CC Barr virus (EBV) transformed B-lymphoblastoid cell line with isolated
 CC PBL, or short-term culturing of PBL by phytohaemagglutinin (PHA)
 CC stimulation, treating the cell line or short-term culture with protein
 CC synthesis inhibitor and immediately extracting RNA from the cultures. The
 CC RNA is then amplified and peptide fragments are obtained by in vitro
 CC transcription/translation of amplified fragments. Mutation analysis of
 CC NF1 is used for detection of frame shift, mis-sense and silent mutations
 CC in various exons of the gene. This is useful in screening for NF1
 CC mutations in young children who are often oligosymptomatic. Efficacy of a
 CC drug or agent can be identified by a screening process in which the
 CC modulation is monitored in vitro using cell systems in which the
 CC defective NF1 gene is expressed. The sequences can be used to design
 CC drugs which modulate NF1 activity, by using knowledge of the structure of
 CC the NF1 protein and of specific defects of the various NF1 mutant
 CC proteins. The method allows for reliable analysis of mutations that are
 CC difficult to detect due to unstable or wrong-spliced transcripts
 XX
 SQ Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 49;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 97 TCTCCAGTGAAGACTTT 113
 DB 17 TTTCCAGTGAAGACTTT 1
 RESULT 51
 ABV85336/c
 ID ABV85336 standard; DNA; 17 BP.
 XX
 AC ABV85336;
 XX
 DT 11-DEC-2002 (first entry)
 XX
 DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:329.

XX
 KW Human; UDP-GalNAC:polypeptide N-acetylgalactosaminyltransferase 10;
 KW pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
 ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN EP1243660-A2.
 XX
 PD 25-SEP-2002.
 XX
 PF 25-JAN-2002; 2002EP-00001161.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 30-AUG-2001; 2001US-0315984P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Zhang J, Gu Y, Nguyen C;
 XX
 DR WPI; 2002-724954/79.
 XX
 PT Nucleic acid encoding human UDP-GalNAC:polypeptide N-
 PT cetylglactosaminyltransferase 10 protein is useful to diagnose, prevent
 PT and treat disorders associated with reduced or over expression of the
 PT encoded protein.
 XX
 PS Example 2; SEQ ID NO 329; 59pp; English.
 XX
 CC The present invention describes an isolated nucleic acid (I) encoding a
 CC human UDP-GalNAC:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
 CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
 CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
 CC present invention can be used in therapy, particularly to prevent or
 CC treat a disorder associated with decreased expression or activity of pp-
 CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
 CC ABP53504 are given in the exemplification of the present invention. N.B.
 CC The sequence data for this patent is not represented in the printed
 CC specification but is based on sequence information supplied by the
 CC European Patent Office
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 49;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 311 CACCATAACCTTAGATG 327
 DB 17 CACCATAACCTTCAATG 1
 RESULT 52
 ABT36459
 ID ABT36459 standard; DNA; 17 BP.
 XX
 AC ABT36459;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 2096.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX

OS Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004208.

XX 17-SEP-2001; 2001PR-00011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Anson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX

PS Disclosure; Page 278; 720pp; French.

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX

SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 49;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 185 GATCATCTAGTGTGAATG 201

Db 1 GATCTCTAGTGTAAATG 17

RESULT 53

ABZ60950

ID ABZ60950 standard; RNA; 17 BP.

XX AC ABZ60950;

XX 21-MAR-2003 (first entry)

XX Human K-Ras DNzyme substrate #1062.

DE Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;

KW anti-rheumatic; cancer; AIDS; ss.

XX

OS

XX Homo sapiens.

XX WO200297114-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-US016840.

XX 29-MAY-2001; 2001US-0294140P.

XX 06-JUN-2001; 2001US-0296249P.

XX 10-SEP-2001; 2001US-0318471P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J;

XX WPI; 2003-140484/13.

XX Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX

PS Claim 58; Page 105; 185pp; English.

CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 CC ribozymes of the invention
 XX

SQ Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 49;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 33 CTTGAAGAAATATCTTA 49

Db 1 CUUGAAGAAUAGUCAUA 17

RESULT 54

ADB40481/c

ID ADB40481 standard; DNA; 17 BP.

XX AC ADB40481;

XX 18-DEC-2003 (revised)

XX 04-DEC-2003 (first entry)

XX Tumour suppression/reversion associated nucleotide #804.

XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.

XX Homo sapiens.

XX WO2003040369-A2.

XX 15-MAY-2003.

XX 17-SEP-2002; 2002WO-IB004219.

XX 17-SEP-2001; 2001FR-00011981.

XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Amson R, Tuijnder M;
 XX DR WPI; 2003-441574/41.
 XX PT New nucleic acid encoding human prostate membrane-specific antigen,
 XX PT useful e.g. for treatment of tumors and viral infection, also related
 XX PT polypeptide and antibodies.
 XX PS Disclosure; Page 126; 771pp; French.
 XX CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and/or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX SQ Sequence 17 BP; 2 A; 1 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 49;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 172 CCAAGCTACATGATC 188
 Db 17 CAAACCCACATGATC 1
 RESULT 55
 AAV93839/C
 ID AAV93839 standard; RNA; 15 BP.
 AC AAV93839;
 DT 18-FEB-1999 (first entry)
 DE Target sequence with sequence homology to c-raf and A-raf position 1754.
 XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
 KW screening; identification; synthesis; deprotection; purification; cancer;
 KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
 KW restenosis; rheumatoid arthritis; ss.
 XX Homo sapiens.
 OS
 XX WO9850530-A2.
 PN
 XX 12-NOV-1998.
 PD
 XX 05-MAY-1998; 98WO-US009249.
 PF
 XX 09-MAY-1997; 97US-0046059P.
 PR
 XX 09-JUN-1997; 97US-0049002P.
 PR
 XX 03-JUL-1997; 97US-0051718P.
 PR
 XX 22-AUG-1997; 97US-0056808P.
 PR

PR 02-OCT-1997; 97US-0061321P.
 PR 02-OCT-1997; 97US-0061324P.
 PR 05-NOV-1997; 97US-0064866P.
 PR 19-DEC-1997; 97US-0068212P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX PA
 XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
 PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
 PI Thompson J, Workman CT, Beaudry A, Sweedler D;
 XX WPI; 1999-009494/01.
 XX DR
 XX PT Identifying new catalytic nucleic acid that modulates selected processes
 PT - especially ribozymes that cleave Raf RNA for treating cancer,
 PT restenosis, and also new ribozymes and modified nucleoside triphosphates
 PT used as antiviral agents and synthons.
 XX Claim 180; Page 176; 259pp; English.
 XX CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules with
 CC endonuclease activity and catalytic activity, from the present invention,
 CC are used to modulate gene expression in plant and mammalian cells and to
 CC cleave target nucleic acid, particularly for treating systemic diseases
 CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 CC ascites and infection. They may also be used to detect genetic drift and
 CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
 CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
 CC generally any condition associated with the level of c-raf. Introduction
 CC of sugar/phosphate modifications increases stability against nuclease and
 CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
 CC method, specifically for modulating the expression of a Raf gene
 XX SQ Sequence 15 BP; 2 A; 1 C; 4 G; 0 T; 8 U; 0 Other;
 Query Match 2.1%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 46;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 370 CCACCATAAAGAGAA 384
 Db 15 CCACCATAAAGATAA 1
 RESULT 56
 AAQ28744
 ID AAQ28744 standard; DNA; 16 BP.
 XX AC AAQ28744;
 XX DT 01-MAR-1993 (first entry)
 XX DE Probe for anti-CEA specific antibody DNA.
 XX Human; carcinoembryonic antigen; heavy chain; light chain; variable;
 KW region; diagnostic; tumour; markers; targeting; ss.
 OS Synthetic.
 XX JP04234987-A.
 PN
 XX 24-AUG-1992.
 PD
 XX 28-DEC-1990; 90JP-00408810.
 PF
 XX 28-DEC-1990; 90JP-00408810.
 PR

XX (MITU) MITSUBISHI KASEI CORP.
 XX WPI; 1992-327631/40.
 XX New DNA fragments encoding variable regions of ABS specific for human CEA
 PT - for diagnosing and monitoring tumours, as tumour markers and for
 PT treatment of tumours.
 XX
 XX Disclosure; page 4; 7pp; Japanese.
 XX The probe was used to hybridise to a cDNA library prepd. from mRNA obtd.
 CC from hybridomas producing anti-CEA-specific antibodies. The cloned DNA
 CC encodes either the heavy chain or light chain variable region of anti-CEA
 CC murine monoclonal antibody. The DNA fragments are useful as diagnostic
 CC agents, as tumour markers for digestive organs, for diagnosis of
 CC malignant tumours; for monitoring after cancer operations, to follow up
 CC bloodless therapy or as therapeutic agents in passive immune therapy and
 CC targetting therapy. See also AAQ28745-7
 XX
 XX Sequence 16 BP; 2 A; 1 C; 8 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 2.1%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 49;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 323 AGATGGGGGTGCT 337
 DB 1 AGATGGGGGTGCTG 15

RESULT 57
 AAV48633
 ID AAV48633 standard; DNA; 16 BP.
 XX
 AC AAV48633;
 XX
 DT 15-OCT-1998 (first entry)
 DE junB gene antisense oligonucleotide JunB-N-19.
 XX junB; junD; antisense oligonucleotide; modulate; gene expression; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX
 XX EP856579-A1.
 PN
 XX
 PD 05-AUG-1998.
 XX
 XX 31-JAN-1997; 97EP-00101531.
 PF
 XX 31-JAN-1997; 97EP-00101531.
 PR
 XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
 PA
 XX Schlingensiepen K, Brysch W;
 PI
 XX WPI; 1998-400310/35.
 DR
 XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
 PT consecutive guanosine or inosine - and have specific ratio of residues
 PT able to form two or three hydrogen bonds, have greater activity and
 PT reduced toxicity, used therapeutically or to modulate growth of cells in
 PT culture.
 XX
 XX Example 3; Fig 5b; 286pp; English.
 PS
 XX AAV4864-708 represent antisense oligonucleotides directed against the
 CC junB and junD genes. Of these, only oligonucleotides AAV48565-614
 CC resulted in effective downregulation of negative growth control by JunB
 CC or JunD, while AAV48615-708 had little effect. The oligonucleotides
 CC exemplify the invention. The specification describes oligonucleotides

CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
 CC can each form three hydrogen bonds to cytosine; do not contain four
 CC consecutive nucleotides able to form three H-bonds each to four
 CC consecutive cytosines; do not contain two sequences of three consecutive
 CC nucleotides each able to form three H-bonds to three consecutive
 CC cytosines, and the ratio between residues able to form two H-bonds each
 CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
 CC oligonucleotides are used to modulate expression of genes, particularly
 CC the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
 CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
 CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
 CC oligonucleotides can also be used to analyse function of proteins (by
 CC altering their expression or activity) and therapeutically, e.g. in cases
 CC of cancer or (targeting TGF) for stimulating the immune system
 XX
 XX Sequence 16 BP; 6 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
 SQ

Query Match 2.1%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 49;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 586 ATTTTATTCATATG 600
 DB 2 ATTATATTCATATG 16

Search completed: September 30, 2004, 16:30:57
 Job time : 1 secs

This Page Blank (uspto)

This Page Blank (uspto)


```
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/308,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12576
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-12576

Query Match          9.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0.35;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 446 TTATGAGAGCATAGCCCAAGGAGCTTGACCTGGAGTGAAGTTCGCATTGAACCTCTAC 505
Db 1 TTATGAGAGCATAGCCCAAGGAGCTTGACCTGGAGTGAAGTTCGCATTGAACCTCTAC 60

RESULT 3
US-10-431-598-18/c
; Sequence 18, Application US/10431598
; Publication No. US20040097454A1
; GENERAL INFORMATION:
; APPLICANT: Klemm, Dwight J.
; APPLICANT: Reusch, Jane E.
; TITLE OF INVENTION: METHOD FOR MODULATION OF CELL PHENOTYPE
; FILE REFERENCE: 2848-34 (now 5111-1)
; CURRENT APPLICATION NUMBER: US/10/431,598
; CURRENT FILING DATE: 2003-05-06
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:probe
US-10-431-598-18

Query Match          8.0%; Score 51; DB 1; Length 60;
Best Local Similarity 91.5%; Pred. No. 1.13;
Matches 54; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 63 ATGTGTGATGCTTTGTAGTACCTCGAAACTGTCTCCAGTGAAGAACTTTGATGATTA 121
Db 60 ATGTGTGATGCTTTGTGGACCTGGAGACTTGTCTCCAGTGAAGAACTTCGATGATTA 2

RESULT 4
US-10-131-827-8002
; Sequence 8002, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; FILE REFERENCE: 506612000120
```

```
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8002
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-8002
```

```
Query Match          7.9%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 539 TTGTGTTTTCCCTGATTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 588
Db 1 TTGTGTTTTCCCTGATTAGCAAGCAAGTAATTTTCTCCCAAGCTGATT 50
```

RESULT 5

```
US-10-688-572-17/c
; Sequence 17, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-17
```

```
Query Match          5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 237 AAAAATACTGAGATTTCTTCTACTACTGGCCAG 269
Db 33 AAAAATACTGAGATTTCTTCTACTACTGGCCAG 1
```

RESULT 6

```
US-10-688-379-17/c
; Sequence 17, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
```

; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-17

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AAAAATAGTGAATTCCTTCATCTGGGCCAG 269
DB 33 AAAAATAGTGAATTCCTTCATCTGGGCCAG 1

RESULT 7

US-10-688-380-17/c
; Sequence 17, Application US/10688380
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-17

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237'AAAAATAGTGAATTCCTTCATCTGGGCCAG 269
DB 33 AAAAATAGTGAATTCCTTCATCTGGGCCAG 1

RESULT 8

US-10-688-572-16/c
; Sequence 16, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17

; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-16

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 9

US-10-688-379-16/c
; Sequence 16, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-16

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 10

US-10-688-380-16/c
; Sequence 16, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927

; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-16

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 11

US-10-384-491-281/c
; Sequence 281, Application US/10384491
; Publication No. US20030224040A1
; GENERAL INFORMATION:

; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: BAYLIN, Stephen B.
; APPLICANT: HERMAN, James

; APPLICANT: Suzuki, Hiromu
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED GENES ASSOCIATED WITH

; FILE REFERENCE: JHU1850-1
; CURRENT APPLICATION NUMBER: US/10/384,491
; CURRENT FILING DATE: 2003-03-07

; PRIOR APPLICATION NUMBER: US 60/362,422
; PRIOR FILING DATE: 2002-03-07

; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 281
; LENGTH: 27

; TYPE: DNA
; ORGANISM: Artificial sequence

; FEATURE:
; OTHER INFORMATION: Amplification primer

US-10-384-491-281

Query Match 4.3%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 588 TTTATCAATATGGTTACGTTGGTTAA 614
DB 27 TTTATCAATATGGTTACGTTGGTTAA 1

RESULT 12

US-09-853-798-15/c
; Sequence 15, Application US/09853798
; Patent No. US20020103193A1
; GENERAL INFORMATION:

; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.

; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: pm431, patin2.1

; CURRENT APPLICATION NUMBER: US/09/853,798
; CURRENT FILING DATE: 2001-05-11

; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 15
; LENGTH: 26

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer

US-09-853-798-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTTGCTCCAGTGAACCTTTGA 115
DB 26 AAACCTTGCTCCAGTGAACCTTTGA 1

RESULT 13

US-09-854-302-15/c
; Sequence 15, Application US/09854302
; Patent No. US20020165228A1
; GENERAL INFORMATION:

; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.

; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: pm431, patin2.1

; CURRENT APPLICATION NUMBER: US/09/854,302
; CURRENT FILING DATE: 2001-10-15

; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 15
; LENGTH: 26

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer

US-09-854-302-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTTGCTCCAGTGAACCTTTGA 115
DB 26 AAACCTTGCTCCAGTGAACCTTTGA 1

RESULT 14

US-09-990-461B-15/c
; Sequence 15, Application US/09990461B
; Publication No. US20030083329A1
; GENERAL INFORMATION:

; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.

; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: pm431, patin2.1

; CURRENT APPLICATION NUMBER: US/09/990,461B
; CURRENT FILING DATE: 2001-11-21

; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 15
; LENGTH: 26

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer

US-09-990-461B-15

Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTTGCTCCAGTGAACCTTTGA 115
DB 26 AAACCTTGCTCCAGTGAACCTTTGA 1

RESULT 15

US-10-688-572-15/c


```
; Sequence 15, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; PRIOR FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-15

Query Match          4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAACTTTGA 1

RESULT 16
US-10-688-379-15/c
; Sequence 15, Application US/10689379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; PRIOR FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-15

Query Match          4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAACTTTGA 1

RESULT 17
US-10-688-380-15/c
; Sequence 15, Application US/10688380
```

```
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-15

Query Match          4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAACTTTGA 1

RESULT 18
US-10-384-491-282
; Sequence 282, Application US/10384491
; Publication No. US20030224040A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: BAYLIN, Stephen B.
; APPLICANT: HERMAN, James
; APPLICANT: Suzuki, Hiroshi
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED GENES ASSOCIATED WITH C
; FILE REFERENCE: JH01850-1
; CURRENT APPLICATION NUMBER: US/10/384,491
; CURRENT FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/362,422
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 282
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Amplification primer
US-10-384-491-282

Query Match          3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 AGGATGATAAACTGGTGGGAAT 414
Db 1 AGGATGATAAACTGGTGGGAAT 24

RESULT 19
US-10-688-572-19/c
; Sequence 19, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
```

```

; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-19

```

```

Query Match          3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 293 TGACAGGAAAGTCAAGAGCACCAT 316
DB 24 TGACAGGAAAGTCAAGAGCACCAT 1

```

```

RESULT 20
US-10-688-379-19/c
; Sequence 19, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-19

```

```

Query Match          3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 293 TGACAGGAAAGTCAAGAGCACCAT 316
DB 24 TGACAGGAAAGTCAAGAGCACCAT 1

```

```

RESULT 21
US-10-688-380-19/c
; Sequence 19, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli

```

```

; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-19

```

```

Query Match          3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 293 TGACAGGAAAGTCAAGAGCACCAT 316
DB 24 TGACAGGAAAGTCAAGAGCACCAT 1

```

```

RESULT 22
US-10-688-572-18/c
; Sequence 18, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-18

```

```

Query Match          3.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 270 GAATTTGACGAGTCACTGCAGA 292
DB 23 GAATTTGACGAGTCACTGCAGA 1

```

```

RESULT 23
US-10-688-379-18/c
; Sequence 18, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T

```

```
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-18

Query Match      3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 GAATTGACGAAGTCACCTGCAGA 292
DB 23 GAATTGACGAAGTCACCTGCAGA 1

RESULT 24
US-10-688-380-18/c
; Sequence 18, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-18

Query Match      3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 GAATTGACGAAGTCACCTGCAGA 292
DB 23 GAATTGACGAAGTCACCTGCAGA 1

RESULT 25
US-10-348-480B-24/c
; Sequence 24, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
```

```
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-24

Query Match      3.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 TGAGAGACATACCAAGG 469
DB 21 TGAGAGACATACCAAGG 1

RESULT 26
US-09-952-522B-27/c
; Sequence 27, Application US/09952522B
; Publication No. US20030092152A1
; GENERAL INFORMATION:
; APPLICANT: Katz, Adam J.
; APPLICANT: Lluall, Ramon
; APPLICANT: Futrell, J. William
; APPLICANT: Hedrick, Marc H.
; APPLICANT: Benhaim, Prosper
; APPLICANT: Lorenz, Hermann Peter
; APPLICANT: Zhu, Min
; TITLE OF INVENTION: ADIPOSE-DERIVED STEM CELLS AND LATTICES
; FILE REFERENCE: 30448.77US11
; CURRENT APPLICATION NUMBER: US/09/952,522B
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: PCT/US00/06232
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: 60/123,711
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/162,462
; PRIOR FILING DATE: 1999-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ap2 forward
; OTHER INFORMATION: primer
US-09-952-522B-27

Query Match      3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 353 ATGGGATGGAAATCAACCA 372
DB 20 ATGGGATGGAAATCAACCA 1

RESULT 27
US-10-416-090-15
; Sequence 15, Application US/10416090
; Publication No. US20040071711A1
; GENERAL INFORMATION:
; APPLICANT: Bicknell, Roy
; APPLICANT: Huminiecki, Lukasz
```

; TITLE OF INVENTION: IMAGING, DIAGNOSIS AND TREATMENT OF
; FILE REFERENCE: DISEASE
; CURRENT APPLICATION NUMBER: US/10416090
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: PCT/US01/04906
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: US 60/245,566
; PRIOR FILING DATE: 2000-11-06
; PRIOR APPLICATION NUMBER: US 60/273,662
; PRIOR FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-416-090-15

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 TGCAGCTTCCTCTCACCCT 35
|||||
DB 1 TGCAGCTTCCTCTCACCCT 20

RESULT 28
US-10-416-090-16/c
; Sequence 16, Application US/10416090
; Publication No. US2004007171A1
; GENERAL INFORMATION:
; APPLICANT: Bicknell, Roy
; APPLICANT: Humilecki, Lukas
; TITLE OF INVENTION: IMAGING, DIAGNOSIS AND TREATMENT OF
; FILE REFERENCE: DISEASE
; FILE REFERENCE: 12795-015U81
; CURRENT APPLICATION NUMBER: US/10416,090
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: PCT/US01/04906
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: US 60/245,566
; PRIOR FILING DATE: 2000-11-06
; PRIOR APPLICATION NUMBER: US 60/273,662
; PRIOR FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-416-090-16

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 CAGTGTGAATGGGGATGTA 210
|||||
DB 20 CAGTGTGAATGGGGATGTA 1

RESULT 29
US-09-795-917-33
; Sequence 33, Application US/09795917
; Publication No. US2004017533A1
; GENERAL INFORMATION:
; APPLICANT: Zehentner et al.

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES
; FILE REFERENCE: CIBT-901-083
; CURRENT APPLICATION NUMBER: US/09/795,917
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/186,058
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-795-917-33

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 63 ATGTGTGATGCTTTTGTAGG 82
|||||
DB 1 ATGTGTGATGCTTTTGTAGG 20

RESULT 30
US-10-348-480B-11
; Sequence 11, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-11

Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 GGTACTGTGAACTTGTCTC 100
|||||
DB 1 GGTACTGTGAACTTGTCTC 20

RESULT 31
US-10-348-480B-12/c
; Sequence 12, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-12

Query Match
Best Local Similarity 3.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 471 CGTGCACCTGGACTGAAGTT 490
DB 20 CGTGCACCTGGACTGAAGTT 1

RESULT 32
US-09-795-917-34/c
; Sequence 34, Application US/09795917
; Publication No. US20040171533A1
; GENERAL INFORMATION:
; APPLICANT: Zehentner et al.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES
; FILE REFERENCE: CIBT-P01-083
; CURRENT APPLICATION NUMBER: US/09/795,917
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/186,058
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 34
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-795-917-34

Query Match
Best Local Similarity 3.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 347 GCAGAAATGGGATGGAAAA 365
DB 19 GCAGAAATGGGATGGAAAA 1

RESULT 33
US-10-348-480B-23
; Sequence 23, Application US/10348480B
; Publication No. US20030175957A1
; GENERAL INFORMATION:
; APPLICANT: Nestec A.G.
; TITLE OF INVENTION: Pre-adipose cell lines
; FILE REFERENCE: 88265-6004
; CURRENT APPLICATION NUMBER: US/10/348,480B
; CURRENT FILING DATE: 2003-03-25
; PRIOR APPLICATION NUMBER: EP 00115489.7
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/EP01/08165
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-23

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
; FEATURE:
; OTHER INFORMATION: DNA
US-10-348-480B-12

Query Match
Best Local Similarity 3.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 399 AAACCTGGTGGTGAATGCG 417
DB 1 AAACCTGGTGGTGAATGCG 19

RESULT 34
US-10-688-572-20/c
; Sequence 20, Application US/10688572
; Publication No. US20040162352A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Treating Syndrome X with Substituted Tetralins and Indanes
; FILE REFERENCE: PRD-0050
; CURRENT APPLICATION NUMBER: US/10/688,572
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-572-20

Query Match
Best Local Similarity 100.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGCGTCACTT 435
DB 19 GTCATGAAGCGTCACTT 1

RESULT 35
US-10-688-379-20/c
; Sequence 20, Application US/10688379
; Publication No. US20040167211A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith T
; APPLICANT: Ambler, Jung Lee
; APPLICANT: Matthews, Jay M
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: METHODS OF USING SUBSTITUTED TETRALINS AND INDANES
; FILE REFERENCE: PRD-0049 NP
; CURRENT APPLICATION NUMBER: US/10/688,379
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/420,026
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,788
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-379-20

Query Match
Best Local Similarity 3.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; OTHER INFORMATION: Description of Artificial Sequence: ap2 reverse
; OTHER INFORMATION: primer
US-09-952-522B-28

Query Match          3.0%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACCTT 435
Db 19 GTCATGAAGGCGTCACCTT 1

RESULT 36
US-10-688-380-20/c
; Sequence 20, Application US/10688380
; Publication No. US20040171680A1
; GENERAL INFORMATION:
; APPLICANT: Janssen Pharmaceutica, N.V.
; APPLICANT: Chen, Xiaoli
; APPLICANT: Demarest, Keith
; APPLICANT: Lee, Jung
; APPLICANT: Matthews, Jay M.
; APPLICANT: Rybczynski, Philip
; TITLE OF INVENTION: Substituted Tetralins and Indanes
; FILE REFERENCE: PRD0048 NP
; CURRENT APPLICATION NUMBER: US/10/688,380
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,927
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 60/495,758
; PRIOR FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-688-380-20

Query Match          3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACCTT 435
Db 19 GTCATGAAGGCGTCACCTT 1

RESULT 37
US-09-952-522B-28
; Sequence 28, Application US/09952522B
; Publication No. US20030082152A1
; GENERAL INFORMATION:
; APPLICANT: Katz, Adam J.
; APPLICANT: Llull, Ramon
; APPLICANT: Futrell, J. William
; APPLICANT: Hedrick, Marc H.
; APPLICANT: Benhaim, Prosper
; APPLICANT: Lorenz, Hermann Peter
; APPLICANT: Zhu, Min
; TITLE OF INVENTION: ADIPOSE-DERIVED STEM CELLS AND LATTICES
; FILE REFERENCE: 30448.77U11
; CURRENT APPLICATION NUMBER: US/09/952,522B
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: PCT/US00/06232
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: 60/123,711
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/162,462
; PRIOR FILING DATE: 1999-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: ap2 reverse
; OTHER INFORMATION: primer
US-09-952-522B-28

Query Match          3.0%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 259 TACTGGCCAGGAATTGA 277
Db 1 TACTGGCCAGGAATTGA 19

RESULT 38
US-10-116-265-8
; Sequence 8, Application US/10116265
; Publication No. US20030077612A1
; GENERAL INFORMATION:
; APPLICANT: Ekblom, Jonas
; TITLE OF INVENTION: NEW METHOD
; FILE REFERENCE: 13425-105001
; CURRENT APPLICATION NUMBER: US/10/116,265
; CURRENT FILING DATE: 2002-04-04
; PRIOR APPLICATION NUMBER: SE 0101218-6
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/281,384
; PRIOR FILING DATE: 2001-04-05
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-116-265-8

Query Match          2.8%; Score 18; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 35;
Matches 14; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 9 AGGAGGGTGCAGCTTCCT 26
Db 1 AGGAGGGTGCAGCTTCCT 18

RESULT 39
US-10-084-839-3080/c
; Sequence 3080, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Ejs, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: IP, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichov, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsatska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
```

;; TITLE OF INVENTION: RNA Detection Assays
;; FILE REFERENCE: FORS-06666
;; CURRENT APPLICATION NUMBER: US/10/084,839
;; CURRENT FILING DATE: 2002-02-26
;; NUMBER OF SEQ ID NOS: 4004
;; SOFTWARE: Patent in version 3.1
;; SEQ ID NO 3080
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic
US-10-084-839-3080

Query Match 2.7%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 247 AGATTTCCTTCATCTGGG 265
Db 19 AGATTTCCTTCATCTGGG 1

RESULT 40
US-10-084-839-3086/c
;; Sequence 3086, Application US/10084839
;; Publication No. US20030186238A1
;; GENERAL INFORMATION:
;; APPLICANT: Third Wave Technologies
;; APPLICANT: Allawi, Hatim
;; APPLICANT: Argue, Brad T.
;; APPLICANT: Bartholomay, Christian T.
;; APPLICANT: Chehak, LuAnne
;; APPLICANT: Curtis, Michelle L.
;; APPLICANT: Eis, Peggy S.
;; APPLICANT: Hall, Jeff G.
;; APPLICANT: Ip, Hon S.
;; APPLICANT: Ji, Lin
;; APPLICANT: Kaiser, Michael
;; APPLICANT: Kwiatkowski, Jr., Robert W.
;; APPLICANT: Lukowiak, Andrew A.
;; APPLICANT: Lymaicheva, Victor
;; APPLICANT: Ma, Wufo
;; APPLICANT: Neri, Bruce P.
;; APPLICANT: Olson, Sarah M.
;; APPLICANT: Olson-Munoz, Marilyn C.
;; APPLICANT: Schaefer, James J.
;; APPLICANT: Skrzypczynski, Zbigniew
;; APPLICANT: Takova, Tsetska Y.
;; APPLICANT: Thompson, Lisa C.
;; TITLE OF INVENTION: RNA Detection Assays
;; FILE REFERENCE: FORS-06666
;; CURRENT APPLICATION NUMBER: US/10/084,839
;; CURRENT FILING DATE: 2002-02-26
;; NUMBER OF SEQ ID NOS: 4004
;; SOFTWARE: Patent in version 3.1
;; SEQ ID NO 3086
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic
US-10-084-839-3086

Query Match 2.7%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 247 AGATTTCCTTCATCTGGG 265
Db 19 AGATTTCCTTCATCTGGG 1

RESULT 41
US-10-084-839-3083/c
;; Sequence 3083, Application US/10084839
;; Publication No. US20030186238A1
;; GENERAL INFORMATION:
;; APPLICANT: Third Wave Technologies
;; APPLICANT: Allawi, Hatim
;; APPLICANT: Argue, Brad T.
;; APPLICANT: Bartholomay, Christian T.
;; APPLICANT: Chehak, LuAnne
;; APPLICANT: Curtis, Michelle L.
;; APPLICANT: Eis, Peggy S.
;; APPLICANT: Hall, Jeff G.
;; APPLICANT: Ip, Hon S.
;; APPLICANT: Ji, Lin
;; APPLICANT: Kaiser, Michael
;; APPLICANT: Kwiatkowski, Jr., Robert W.
;; APPLICANT: Lukowiak, Andrew A.
;; APPLICANT: Lymaicheva, Victor
;; APPLICANT: Ma, Wufo
;; APPLICANT: Neri, Bruce P.
;; APPLICANT: Olson, Sarah M.
;; APPLICANT: Olson-Munoz, Marilyn C.
;; APPLICANT: Schaefer, James J.
;; APPLICANT: Skrzypczynski, Zbigniew
;; APPLICANT: Takova, Tsetska Y.
;; APPLICANT: Thompson, Lisa C.
;; TITLE OF INVENTION: RNA Detection Assays
;; FILE REFERENCE: FORS-06666
;; CURRENT APPLICATION NUMBER: US/10/084,839
;; CURRENT FILING DATE: 2002-02-26
;; NUMBER OF SEQ ID NOS: 4004
;; SOFTWARE: Patent in version 3.1
;; SEQ ID NO 3083
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic
US-10-084-839-3083

Query Match 2.7%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 246 GAGATTTCCTTCATCTGG 264
Db 19 GAGATTTCCTTCATCTGG 1

RESULT 42
US-09-972-211-164
;; Sequence 164, Application US/09972211
;; Publication No. US20040049245A1
;; GENERAL INFORMATION:
;; APPLICANT: Shimkets, Richard A
;; APPLICANT: Taupier, Jr., Raymond J
;; APPLICANT: Burgess, Catherine E
;; APPLICANT: Zerhusen, Bryan D
;; APPLICANT: Mezes, Peter S
;; APPLICANT: Rastelli, Luca
;; APPLICANT: Malyankar, Uriel M
;; APPLICANT: Grosse, William M
;; APPLICANT: Alsobrook II, John P
;; APPLICANT: Lepley, Denise M
;; APPLICANT: Spytek, Kimberly Ann
;; APPLICANT: Li, Li
;; APPLICANT: Edinger, Shlomit
;; APPLICANT: Gerlach, Valerie

; APPLICANT: Ellerman, Karen
 ; APPLICANT: MacDougall, John R
 ; APPLICANT: Gunther, Erik
 ; APPLICANT: Millet, Isabelle
 ; APPLICANT: Stone, David J
 ; APPLICANT: Smithson, Glennnda
 ; APPLICANT: Szekeres Jr, Edward S
 ; TITLE OF INVENTION: No. US20040049245A1el Human Proteins, Polynucleotides Encoding TH
 ; FILE OF INVENTION: Methods Of Using The Same
 ; FILE REFERENCE: 21402-141
 ; CURRENT APPLICATION NUMBER: US/09/972,211
 ; PRIOR FILING DATE: 2001-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,325
 ; PRIOR FILING DATE: 2000-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,323
 ; PRIOR FILING DATE: 2000-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,400
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,397
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,401
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,379
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,402
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,384
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,373
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,372
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,383
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,382
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/275,892
 ; PRIOR FILING DATE: 2001-03-14
 ; PRIOR APPLICATION NUMBER: 60/296,860
 ; PRIOR FILING DATE: 2001-06-08
 ; NUMBER OF SEQ ID NOS: 198
 ; SOFTWARE: Patentin Ver. 2.1
 ; SEQ ID NO 164
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Ag2456 PCR
 ; OTHER INFORMATION: Sequence
 US-09-972-211-164

Query Match 2.6%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 45;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 GTGGTGGATGCGTCATGAA 424
 Db 2 GTGGTGGAGTGTGTCATGAA 21

RESULT 43
 US-10-096-625-164
 ; Sequence 164, Application US/10096625
 ; Publication No. US20040068095A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Shimkets, Richard A
 ; APPLICANT: Taupier Jr, Raymond J
 ; APPLICANT: Burgess, Catherine E
 ; APPLICANT: Zerhusen, Bryan D
 ; APPLICANT: Mezas, Peter S
 ; APPLICANT: Rastelli, Luca
 ; APPLICANT: Malyankar, Uriel M
 ; APPLICANT: Grosse, William M

; APPLICANT: Alsobrook II, John P
 ; APPLICANT: Lepley, Denise M
 ; APPLICANT: Spytek, Kimberly Ann
 ; APPLICANT: Li, Li
 ; APPLICANT: Edinger, Shlomit
 ; APPLICANT: Gerlach, Valerie
 ; APPLICANT: Ellerman, Karen
 ; APPLICANT: MacDougall, John R
 ; APPLICANT: Gunther, Erik
 ; APPLICANT: Millet, Isabelle
 ; APPLICANT: Stone, David J
 ; APPLICANT: Smithson, Glennnda
 ; APPLICANT: Szekeres Jr, Edward S
 ; APPLICANT: Ji, Weizhen
 ; TITLE OF INVENTION: No. US20040068095A1el Human Proteins, Polynucleotides Encoding The
 ; FILE OF INVENTION: Methods Of Using The Same
 ; FILE REFERENCE: 21402-141 CIP
 ; CURRENT APPLICATION NUMBER: US/10/096,625
 ; CURRENT FILING DATE: 2002-03-13
 ; PRIOR APPLICATION NUMBER: 09/972,211
 ; PRIOR FILING DATE: 2001-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,325
 ; PRIOR FILING DATE: 2000-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,323
 ; PRIOR FILING DATE: 2000-10-05
 ; PRIOR APPLICATION NUMBER: 60/238,400
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,397
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,401
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,379
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,402
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 30/238,384
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,373
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,372
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,383
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/238,382
 ; PRIOR FILING DATE: 2000-10-06
 ; PRIOR APPLICATION NUMBER: 60/275,892
 ; PRIOR FILING DATE: 2001-03-14
 ; PRIOR APPLICATION NUMBER: 60/296,860
 ; PRIOR FILING DATE: 2001-06-08
 ; NUMBER OF SEQ ID NOS: 200
 ; SOFTWARE: Patentin Ver. 2.1
 ; SEQ ID NO 164
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Ag2456 PCR
 ; OTHER INFORMATION: Sequence
 US-10-096-625-164

Query Match 2.6%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 45;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 GTGGTGGATGCGTCATGAA 424
 Db 2 GTGGTGGAGTGTGTCATGAA 21

RESULT 44
 US-10-084-839-3075/c
 ; Sequence 3075, Application US/10084839
 ; Publication No. US20030186238A1

GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tserska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 3075
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3075

Query Match 2.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 45;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 342 CATGTCGAGAAATGGGATGG 361
||| ||||| ||||| ||||| |||||
Db 20 CAGTGCAGAAATGGGATGG 1

RESULT 45
US-10-238-700-3142/c
; Sequence 3142, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (WBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3142

Query Match 2.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 46;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 8 CAGGAGGGTGCAGCTTC 24
||| ||||| ||||| ||||| |||||
Db 17 CAGGAGGGTTCAGCTTC 1

RESULT 46
US-10-349-143-11444
; Sequence 11444, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11444
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6549 for SEQ 3579, in complemer
US-10-349-143-11444

Query Match 2.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 570 ATTTTCTCCCAAGCTGA 586
||| ||||| ||||| ||||| |||||
Db 1 ATTTTCTCCCAAGCTGA 17

RESULT 47
US-10-349-143-7744
; Sequence 7744, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7744
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:

```
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-21773 for SEQ 3810,
US-10-349-143-7744

Query Match      2.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 51;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 450 GAGAGAGCATAACCCAG 467
Db 1 GAGAGAGCAAAACCCAG 18

RESULT 48
US-10-060-756A-1328
; Sequence 1328, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1328
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1328

Query Match      2.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 58 ACAAAATGTGTGATGC 73
Db 2 ACAAAATGTGTGTC 17

RESULT 49
US-10-060-756A-1329
; Sequence 1329, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1328
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1328

Query Match      2.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 0; Mismatches 1; Indels 1; Gaps 0;

QY 58 ACAAAATGTGTGATGC 73
Db 2 ACAAAATGTGTGTC 17

RESULT 49
US-10-060-756A-1329
; Sequence 1329, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1329

Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 311 CACCAATACCTTAGTG 327
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1329

Query Match      2.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 51;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 58 ACAAAATGTGTGATGC 73
Db 1 ACAAAATGTGTGTC 16

RESULT 50
US-10-060-895A-329/c
; Sequence 329, Application US/10060895A
; Publication No. US2003010403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-329

Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 311 CACCAATACCTTAGTG 327
```

```
Db      17 CACCATACCTCAATG 1
RESULT 51
US-10-156-306-351
; Sequence 351, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 351
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-351
Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 55;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY      451 AGAGAGCATAAGCCAG 467
Db      1 AGAGACUUAAGCCAG 17
RESULT 52
US-10-156-306-5116/c
; Sequence 5116, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5116
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5116
Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      254 CTTCACTCGGCCAGG 270
Db      17 CTTCACTCGGGCTAGG 1
RESULT 53
US-10-156-306-7073/c
; Sequence 7073, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7073
Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      253 CTTCACTCGGCCAG 269
Db      17 CTTCACTCGGGCTAG 1
RESULT 54
US-10-128-560-140/c
; Sequence 140, Application US/10128560
; Publication No. US20030134272A1
; GENERAL INFORMATION:
; APPLICANT: Universiteit Gent
; TITLE OF INVENTION: Improved mutation analysis of the NF1 Gene
; FILE REFERENCE: US-005-PCT
; CURRENT APPLICATION NUMBER: US/10/128,560
; CURRENT FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: EP 99870216.1
; PRIOR FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: EP 00870122.9
; PRIOR FILING DATE: 2000-06-05
; PRIOR APPLICATION NUMBER: US 60/211,929
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 264
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 140
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-128-560-140
Query Match      2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      97 TCTCCAGTGAAGACTTT 113
Db      17 TTCCAGTGAAGACTTT 1
RESULT 55
US-10-128-560-196/c
; Sequence 196, Application US/10128560
; Publication No. US20030134272A1
; GENERAL INFORMATION:
; APPLICANT: Universiteit Gent
; TITLE OF INVENTION: Improved mutation analysis of the NF1 Gene
; FILE REFERENCE: US-005-PCT
; CURRENT APPLICATION NUMBER: US/10/128,560
; CURRENT FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: EP 99870216.1
; PRIOR FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: EP 00870122.9
; PRIOR FILING DATE: 2000-06-05
; PRIOR APPLICATION NUMBER: US 60/211,929
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 264
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 196
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-128-560-196
```

```
Query Match          2.2%   Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 55;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 97 TCTCCAGTGAACACTTT 113
Db 17 TTTCCAGTGAAGACTTT 1

RESULT 56
US-10-238-700-1062
; Sequence 1062, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MEHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1062
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1062

Query Match          2.2%   Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 55;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 33 CTGTGAAGATATCTCTA 49
Db 1 CUUGAAGAAUAGUCAUA 17

RESULT 57
US-10-287-919-1817
; Sequence 1817, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; PRIOR FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 1817
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (1050269)...(1050283)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 2300
US-10-287-919-1817

Query Match          2.1%   Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 53;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 583 CTGATTATTTCAT 597
Db 1 CTGATTATCAAT 15

RESULT 58
```

```
US-10-043-875-276
; Sequence 276, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; PRIOR FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 276
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-276

Query Match          2.1%   Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 AATGGGATGGAAA 364
Db 3 AATGGGATGGAAA 15

RESULT 59
US-10-043-875-278
; Sequence 278, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; PRIOR FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 278
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-278

Query Match          2.1%   Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 AATGGGATGGAAA 364
Db 2 AATGGGATGGAAA 14

RESULT 60
US-10-043-875-274
; Sequence 274, Application US/10043875
; Publication No. US20030054339A1
```

```
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 274
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-274

Query Match          2.1%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 AATGGGATGGAAA 364
Db 4 AATGGGATGGAAA 16

RESULT 61
US-10-043-875-277
; Sequence 277, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 277
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-277

Query Match          2.1%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 AATGGGATGGAAA 364
Db 3 AATGGGATGGAAA 15

Search completed: October 1, 2004, 07:06:10
Job time : 1 secs
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 1, 2004, 07:03:27 ; Search time 0.001 Seconds
(without alignments)
580.744 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 25 seqs, 458 residues
Total number of hits satisfying chosen parameters: 50

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 25 summaries

Database : rni2.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	33	5.2	33	1	US-09-853-798A-17
C 2	29	4.6	29	1	US-09-853-798A-16
C 3	26	4.1	26	1	US-09-854-302-15
C 4	26	4.1	26	1	US-09-853-798A-15
C 5	24	3.8	24	1	US-09-853-798A-19
C 6	23	3.6	23	1	US-09-853-798A-18
C 7	19	3.0	19	1	US-09-853-798A-20
C 8	15.4	2.4	18	1	US-09-422-978-11444
C 9	14.8	2.3	18	1	US-09-422-978-7744
C 10	13	2.1	15	1	US-08-571-071B-2
C 11	13	2.1	15	1	US-09-253-977-2
C 12	12.8	2.0	16	1	US-08-753-147-131
C 13	12.8	2.0	16	1	US-08-861-096A-41
C 14	12.8	2.0	16	1	US-09-479-005A-414
C 15	12.4	2.0	15	1	US-08-311-760A-235
C 16	12.4	2.0	15	1	US-08-182-968A-484
C 17	12.4	2.0	15	1	US-08-334-847-299
C 18	12.4	2.0	15	1	US-08-334-847-492
C 19	12.4	2.0	15	1	US-08-292-620A-691
C 20	12.4	2.0	15	1	US-08-774-306A-484
C 21	12.4	2.0	15	1	US-08-774-310-235
C 22	12.4	2.0	15	1	US-09-064-156A-484
C 23	12.4	2.0	15	1	US-09-071-845-691
C 24	12	1.9	14	1	US-09-291-541-25
C 25	12	1.9	15	1	US-08-311-486C-736

ALIGNMENTS

RESULT 1
US-09-853-798A-17/c
; Sequence 17, Application US/09853798A

; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, Patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 33.
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-17

Query Match 5.2%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 0.46;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AAAAATACTGAGATTCTTCATCTACTGGCCAG 269
DB 33 AAAAATACTGAGATTCTTCATCTACTGGCCAG 1

RESULT 2
US-09-853-798A-16/c
; Sequence 16, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, Patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-16

Query Match 4.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.94;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 208 TGATCACCATTAAATCTGAAAGTACCTTT 236
DB 29 TGATCACCATTAAATCTGAAAGTACCTTT 1

RESULT 3
US-09-854-302-15/c
; Sequence 15, Application US/09854302
; Patent No. 6555536
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: pm431, Patin2.1
; CURRENT APPLICATION NUMBER: US/09/854,302
; CURRENT FILING DATE: 2001-10-15
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-854-302-15
Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 90 AAACCTGTCTCCAGTGAAACCTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAACCTTTGA 1
RESULT 4
US-09-853-798A-15/c
; Sequence 15, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-15
Query Match 4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 90 AAACCTGTCTCCAGTGAAACCTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAACCTTTGA 1
RESULT 5
US-09-853-798A-19/c
; Sequence 19, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-19
Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.2;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 293 TGACAGGAAAGTCAGAGCACCACAT 316
Db 24 TGACAGGAAAGTCAGAGCACCACAT 1
RESULT 6
US-09-853-798A-18/c
; Sequence 18, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-18
Query Match 3.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.5;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 270 GAATTGGACGAGTCAGTCGAGA 292
Db 23 GAATTGGACGAGTCAGTCGAGA 1
RESULT 7
US-09-853-798A-20/c
; Sequence 20, Application US/09853798A
; Patent No. 6599899
; GENERAL INFORMATION:
; APPLICANT: Rybczynski, Philip
; APPLICANT: et al.
; TITLE OF INVENTION: BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES
; FILE REFERENCE: 431565566, patin2.1
; CURRENT APPLICATION NUMBER: US/09/853,798A
; CURRENT FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-853-798A-20
Query Match 3.0%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 417 GTCATGAAGCGCTCAGCTT 435
Db 19 GTCATGAAGCGCTCAGCTT 1
RESULT 8
US-09-422-978-11444
; Sequence 11444, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET-020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
```



```
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11444
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-6549 for SEQ 3579, in complete
US-09-422-978-11444

Query Match          2.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 570 ATTTCTCCCAAGCTCA 586
Db 1 ATTTCTCCCAAGTGA 17

RESULT 9
US-09-422-978-7744
; Sequence 7744, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilva
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7744
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-21773 for SEQ 3810,
US-09-422-978-7744

Query Match          2.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 11;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 450 GAGAGAGCATAGCCCAAG 467
Db 1 GAGAGAGCAAAACCCCAAG 18

RESULT 10
US-08-671-071B-2
; Sequence 2, Application US/08671071B
; Patent No. 5811270
; GENERAL INFORMATION:
; APPLICANT: Grandgenett, Duane
; TITLE OF INVENTION: An in vitro method for concerted integration of
; FILE REFERENCE: donor DNA molecules using retroviral integrase proteins.
; NUMBER OF SEQUENCES: 7
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Grandgenett, Duane
; STREET: 8610 Henrietta Ave
; CITY: Brentwood
; STATE: Missouri
; COUNTRY: USA
; ZIP: 63144
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Distette, 3.5 inch;
; COMPUTER: Gateway 2000,4DX2-66E(Intel)
; OPERATING SYSTEM: IBM clone
; SOFTWARE: Microsoft word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/671,071B
; FILING DATE: 06/27/96
; CLASSIFICATION: 435
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (314) 962-0064
; TELEFAX: (314) 577-8406
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 bases
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE: Combination of avian or HIV-1 retrovirus
; ORIGINAL SOURCE: DNA, pIAN7 plasmid and pGEM plasmid.
; IMMEDIATE SOURCE: Same as in 2.v1.
; FEATURE:
; OTHER INFORMATION: The sequence is the bottom strand of
; OTHER INFORMATION: M-2 U5 and the pGEM target of the top clone shown in
; OTHER INFORMATION: Figure 14 of original application.
US-08-671-071B-2

Query Match          2.1%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 254 CTTCACTACTGGGC 266
Db 1 CTTCACTACTGGGC 13

RESULT 11
US-09-253-977-2
; Sequence 2, Application US/09253977A
; Patent No. 6316261
; GENERAL INFORMATION:
; APPLICANT: Grandgenett, Duane P.
; TITLE OF INVENTION: Method for Analyzing Concerted Integration of DNA Donor
; TITLE OF INVENTION: Molecules into Target DNA and the Enzymes that Perform
; TITLE OF INVENTION: this Concerted Integration Reaction
; FILE REFERENCE: 16153-8244
; CURRENT APPLICATION NUMBER: US/09/253,977A
; CURRENT FILING DATE: 1998-09-21
; EARLIER APPLICATION NUMBER: 08/671,071
; EARLIER FILING DATE: 1996-06-27
; EARLIER APPLICATION NUMBER: 08/247,089
; EARLIER FILING DATE: 1994-05-20
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 2
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Combination
; OTHER INFORMATION: of avian or HIV-1 retrovirus DNA and pIAN7 plasmid
US-09-253-977-2
```

Query Match 2.1%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 254 CTTCACTAGGCG 266
 |||||
 DB 1 CTTCACTAGGCG 13

RESULT 12

US-08-753-147-131
 ; Sequence 131, Application US/08753147
 ; Patent No. 5770372
 ; GENERAL INFORMATION:
 ; APPLICANT: Concannon, Patrick
 ; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
 ; NUMBER OF SEQUENCES: 196
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Christensen O'Connor Johnson and Kindness
 ; STREET: 1420 5th Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98101-2347
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/753,147
 ; FILING DATE:
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Sheiness, Diana K.
 ; REGISTRATION NUMBER: 35,356
 ; REFERENCE/DOCKET NUMBER: VMRC-1-9714
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 743-4387
 ; TELEFAX: (206) 224 0779
 ; INFORMATION FOR SEQ ID NO: 131:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: double
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 ; ORIGINAL SOURCE:
 ; ORGANISM: Homo sapiens
 ; US-08-753-147-131

Query Match 2.0%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 14;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 561 AACAGGTAATTTCT 576
 |||||
 DB 1 AACAGGTAATTTCT 16

RESULT 13

US-08-861-096A-41/c
 ; Sequence 41, Application US/08861096A
 ; Patent No. 5958689
 ; GENERAL INFORMATION:
 ; APPLICANT: Scholin, Christopher A.
 ; APPLICANT: Cangelosi, Gerard A.
 ; APPLICANT: Haydock, Paul V.
 ; TITLE OF INVENTION: Detection of Toxigenic Marine Diatoms of
 ; the Genus Pseudo-nitzschia
 ; NUMBER OF SEQUENCES: 45

; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Townsend and Townsend and Crew LLP
 ; STREET: Two Embarcadero Center, Eighth Floor
 ; CITY: San Francisco
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 94111-3834
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/861,096A
 ; FILING DATE: 21-MAY-1997
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 60/019,143
 ; FILING DATE: 22-MAY-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Weber, Kenneth A.
 ; REGISTRATION NUMBER: 31,677
 ; REFERENCE/DOCKET NUMBER: 017748-000110US
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (415) 576-0200
 ; TELEFAX: (415) 576-0300
 ; INFORMATION FOR SEQ ID NO: 41:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA
 ; US-08-861-096A-41

Query Match 2.0%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 14;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 TGGTGAATCGTCAT 421
 |||||
 DB 16 TGGTGAATCGTCAT 1

RESULT 14

US-09-479-005A-414
 ; Sequence 414, Application US/09479005A
 ; Patent No. 6656731
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
 ; FILE REFERENCE: MEHB00-884-C
 ; CURRENT APPLICATION NUMBER: US/09/479,005A
 ; CURRENT FILING DATE: 2000-01-07
 ; PRIOR APPLICATION NUMBER: US 09/444,209
 ; PRIOR FILING DATE: 1999-11-19
 ; PRIOR APPLICATION NUMBER: US 09/159,274
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: US 60/059,473
 ; PRIOR FILING DATE: 1997-09-22
 ; NUMBER OF SEQ ID NOS: 1208
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 414
 ; LENGTH: 16
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; US-09-479-005A-414

Query Match 2.0%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 56.2%; Pred. No. 14;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 33 CTTGAAGATAATCCT 48

100

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/334,847
;; FILING DATE: NO. 5693532ember 4, 1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/032
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 299:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-334-847-299

Query Match 2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 621 TTTTATAGTTAG 634
Db 15 TTTTATATTTAG 2

RESULT 18 ✓
US-08-334-847-492
; Sequence 492, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwigen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: NO. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 492:

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-334-847-492

Query Match 2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 13;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 236 TAAAAATACAGAGA 249
Db 1 UAAAAUACUCAGA 14

RESULT 19
US-08-292-620A-691/c
; Sequence 691, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 691:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-691

```
Query Match          2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 190 TCAGTGTGAATGG 203
DB 15 TCAGTGTGAATGG 2

RESULT 20
US-08-774-306A-484/c
; Sequence 484, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 484:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-306A-484

Query Match          2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 130 AAGTAGGAGTGGC 143
DB 14 AAGTAGGAGTGGC 1

RESULT 21
US-08-774-310-235/c
; Sequence 235, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
```

```
APPLICANT: Newton, Roger S.
APPLICANT: Ramharack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,310
FILING DATE: December 23, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/311,760
FILING DATE: September 23, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/229
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 235:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-310-235

Query Match          2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 263 GGGCCAGGAAITTG 276
DB 15 GGGCCAGGAAITTG 2

RESULT 22
US-09-064-156A-484/c
; Sequence 484, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/064,156A
FILING DATE: April 21, 1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/774,306
FILING DATE: December 26, 1996
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 234/083
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 484:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-064-156A-484

Query Match 2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 130 AAGTAGGAGTGGC 143
Db 14 AAGTAGGAGTAGGC 1

RESULT 23
US-09-071-845-691/c
Sequence 691, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 691:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-691

Query Match 2.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 13;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 190 TCAGTGTGAATGG 203
Db 15 TCAGTGTGAATGG 2

RESULT 24
US-09-291-541-25
Sequence 25, Application US/09291541
Patent No. 6461864
GENERAL INFORMATION:
APPLICANT: Soriano, Philippe
APPLICANT: Robertson, Elizabeth J.
TITLE OF INVENTION: METHODS AND VECTOR CONSTRUCTS FOR MAKING TRANSGENIC
TITLE OF INVENTION: NON-HUMAN ANIMALS WHICH UBIQUITOUSLY EXPRESS A
FILE REFERENCE: 14538A-44-1
CURRENT APPLICATION NUMBER: US/09/291,541
CURRENT FILING DATE: 1999-04-14
EARLIER APPLICATION NUMBER: US 60/081,894
EARLIER FILING DATE: 1998-04-15
NUMBER OF SEQ ID NOS: 28
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 25
TYPE: DNA
LENGTH: 14
ORGANISM: Encephalomyocarditis virus
US-09-291-541-25

Query Match 1.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GATGATTATATG 125
Db 2 GATGATTATATG 13

RESULT 25
US-08-311-486C-736
Sequence 736, Application US/08311486C
Patent No. 5811300
GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kisich
APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INF-
NUMBER OF SEQUENCES: 1157
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 736:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-736

Query Match 1.9%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 14;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 328 GGGGTGCTCTGG 339
Db 1 GGGGUGUCCUGG 12

Search completed: October 1, 2004, 07:03:27
Job time : 0.001 secs

two

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 30, 2004, 16:29:21 ; Search time 0.001 Seconds
(without alignments)
916.764 Million cell updates/sec

Title: US-09-503-596-2
Perfect score: 634
Sequence: 1 ggaattccaggagggtgcag.....ataacttttttagatttag 634

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 36 seqs, 723 residues
Total number of hits satisfying chosen parameters: 72

Minimum DB seq length: 10
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 36 summaries

Database : rge2.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	33	5.2	33	1 AR361918	ACCESSION:AR361918
C 2	29	4.6	29	1 AR361917	ACCESSION:AR361917
C 3	26	4.1	26	1 AR309143	ACCESSION:AR309143
C 4	26	4.1	26	1 AR361916	ACCESSION:AR361916
C 5	26	4.1	26	1 AR327744	ACCESSION:AR327744
C 6	26	4.1	26	1 AR327819	ACCESSION:AR327819
C 7	26	4.1	26	1 AR338577	ACCESSION:AR338577
C 8	24	3.8	24	1 AR361920	ACCESSION:AR361920
C 9	23	3.6	23	1 AR361919	ACCESSION:AR361919
C 10	20	3.2	20	1 AX282817	ACCESSION:AX282817
C 11	20	3.2	20	1 AX357027	ACCESSION:AX357027
C 12	20	3.2	20	1 AX357028	ACCESSION:AX357028
C 13	19	3.0	19	1 AR361921	ACCESSION:AR361921
C 14	19	3.0	19	1 AX282822	ACCESSION:AX282822
C 15	18.8	3.0	22	1 A98024	ACCESSION:A98024
C 16	17.4	2.7	21	1 AX154043	ACCESSION:AX154043
C 17	16.8	2.6	21	1 AX497397	ACCESSION:AX497397
C 18	15.4	2.4	18	1 AX299709	ACCESSION:AX299709
C 19	14.6	2.3	18	1 AR296009	ACCESSION:AR296009
C 20	14.4	2.3	17	1 AX422118	ACCESSION:AX422118
C 21	14.4	2.3	17	1 AX500021	ACCESSION:AX500021
C 22	14.4	2.3	17	1 AX500032	ACCESSION:AX500032
C 23	14.4	2.3	17	1 AX762488	ACCESSION:AX762488
C 24	14.4	2.2	17	1 AX759766	ACCESSION:AX759766
C 25	13.8	2.2	17	1 AX119483	ACCESSION:AX119483
C 26	13.8	2.2	17	1 AX119539	ACCESSION:AX119539
C 27	13.8	2.2	17	1 AX544816	ACCESSION:AX544816
C 28	13.8	2.2	17	1 AX730462	ACCESSION:AX730462
C 29	13.8	2.2	17	1 AX757483	ACCESSION:AX757483
C 30	13.8	2.2	17	1 AX781960	ACCESSION:AX781960
C 31	13.8	2.2	17	1 AX781961	ACCESSION:AX781961
C 32	13.8	2.2	17	1 BD201505	ACCESSION:BD201505
C 33	13.8	2.2	17	1 BD201506	ACCESSION:BD201506

ALIGNMENTS

RESULT 1	AR361918/c	AR361918	33 bp	DNA	linear	PAT 17-AUG-2003
LOCUS	Sequence 17 from patent US 6599899.					
DEFINITION	AR361918					
ACCESSION	AR361918					
VERSION	AR361918.1	GI:33769929				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 33)					
AUTHORS	Burris,T.P. and Rybczynski,P.J.					
TITLE	Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment					
JOURNAL	Patent: US 6599899-A 17 29-JUL-2003;					
FEATURES	Location/Qualifiers					
source	1..33					
	/organism="unknown"					
	/mol_type="genomic DNA"					
Query Match	5.2%; Score 33; DB 1; Length 33;					
Best Local Similarity	100.0%; Pred. No. 1.2;					
Matches	33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	237 AAAAATCTGAGATTCCTTCATCTACTGGCCAG 269					
DB	33 AAAAATCTGAGATTCCTTCATCTACTGGCCAG 1					
RESULT 2	AR361917/c	AR361917	29 bp	DNA	linear	PAT 17-AUG-2003
LOCUS	Sequence 16 from patent US 6599899.					
DEFINITION	AR361917					
ACCESSION	AR361917					
VERSION	AR361917.1	GI:33769928				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 29)					
AUTHORS	Burris,T.P. and Rybczynski,P.J.					
TITLE	Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment					
JOURNAL	Patent: US 6599899-A 16 29-JUL-2003;					
FEATURES	Location/Qualifiers					
source	1..29					
	/organism="unknown"					
	/mol_type="genomic DNA"					
Query Match	4.6%; Score 29; DB 1; Length 29;					
Best Local Similarity	100.0%; Pred. No. 2.2;					
Matches	29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	208 TGATCACCATTAAATCTGAAAGTACCTTT 236					
DB	29 TGATCACCATTAAATCTGAAAGTACCTTT 1					
RESULT 3	AR309143/c	AR309143	26 bp	DNA	linear	PAT 12-JUN-2003
LOCUS	Sequence 15 from patent US 6555536.					
DEFINITION	AR309143					
ACCESSION	AR309143					
VERSION	AR309143.1	GI:31700985				
KEYWORDS						

```

SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 26)
AUTHORS     Burris,T.P., Combs,D.W. and Rybczynski,P.J.
TITLE       Biologically active 4H-benzo [1,4]oxazin-3-ones
JOURNAL     Patent: US 655536-A 15 29-APR-2003;
FEATURES    Location/Qualifiers
            source
            1..26
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAGAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAGAACTTTGA 1

RESULT 6
AX327819/c
LOCUS      AX327819                26 bp      DNA      linear      PAT 07-JAN-2002
DEFINITION Sequence 15 from Patent WO0187861.
ACCESSION  AX327819
VERSION     AX327819.1 GI:18098092
KEYWORDS   .
SOURCE     synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Burris,T.P., Demarest,K.T., Combs,D.W., Rybczynski,P.J. and
           Turchi,I.J.
TITLE      Methods of treatment using benzoxazinones as peroxisome
           proliferator activated receptor gamma modulators
JOURNAL    Patent: WO 0187861-A 15 22-NOV-2001;
           Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES   Location/Qualifiers
            source
            1..26
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="primer"

Query Match      4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAGAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAGAACTTTGA 1

RESULT 7
AX338577/c
LOCUS      AX338577                26 bp      DNA      linear      PAT 09-JAN-2002
DEFINITION Sequence 15 from Patent WO0187862.
ACCESSION  AX338577
VERSION     AX338577.1 GI:18128972
KEYWORDS   .
SOURCE     synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Burris,T.P., Combs,D.W. and Rybczynski,P.J.
TITLE      Biologically active 4H-benzo 1,4-oxazin-3-ones
JOURNAL    Patent: WO 0187862-A 15 22-NOV-2001;
           Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES   Location/Qualifiers
            source
            1..26
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="primer"

Query Match      4.1%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 90 AAACCTGTCTCCAGTGAAGAACTTTGA 115
Db 26 AAACCTGTCTCCAGTGAAGAACTTTGA 1

RESULT 5
AX327744/c
LOCUS      AX327744                26 bp      DNA      linear      PAT 07-JAN-2002
DEFINITION Sequence 15 from Patent WO0187860.
ACCESSION  AX327744
VERSION     AX327744.1 GI:18098055
KEYWORDS   .
SOURCE     synthetic construct
           artificial sequences.
REFERENCE  1
AUTHORS    Burris,T.P. and Rybczynski,P.J.
TITLE      Novel benzoxazinones as peroxisome proliferator activated receptor
           gamma modulators and method of treatment
JOURNAL    Patent: WO 0187860-A 15 22-NOV-2001;
           Ortho-McNeil Pharmaceutical, Inc. (US)
FEATURES   Location/Qualifiers
            source
            1..26
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="primer"

```

```
RESULT 8
AR361920/c
LOCUS AR361920 24 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 19 from patent US 6599899.
ACCESSION AR361920
VERSION AR361920.1 GI:33769931
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Burris,T.P. and Rybczynski,P.J.
TITLE Benzoxazinones as peroxisome proliferator activated receptor gamma
modulators and method of treatment
JOURNAL Patent: US 6599899-A 19 29-JUL-2003;
FEATURES
LOCATION/Qualifiers
SOURCE
Query Match 3.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0;
QY 293 TGACAGGAAGTCAGAGCACCACAT 316
Db 24 TGACAGGAAGTCAGAGCACCACAT 1
RESULT 9
AR361919/c
LOCUS AR361919 23 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 18 from patent US 6599899.
ACCESSION AR361919
VERSION AR361919.1 GI:33769930
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Burris,T.P. and Rybczynski,P.J.
TITLE Benzoxazinones as peroxisome proliferator activated receptor gamma
modulators and method of treatment
JOURNAL Patent: US 6599899-A 18 29-JUL-2003;
FEATURES
LOCATION/Qualifiers
SOURCE
Query Match 3.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 5.1; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 0;
QY 270 GAATTTGACGAAGTCAGTCGAGA 292
Db 23 GAATTTGACGAAGTCAGTCGAGA 1
RESULT 10
AX282817
LOCUS AX282817 20 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 31 from Patent WO0164238.
ACCESSION AX282817
VERSION AX282817.1 GI:16609817
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Zehentner,B., Leser-Reiff,U. and Burtcher,H.
TITLE Methods and compositions for regulating adipocytes
JOURNAL Patent: WO 0164238-A 31 07-SEP-2001;
Curis, Inc. (US)
```

```
FEATURES
SOURCE
LOCATION/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"
Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 63 ATGTGTCATGCTTTGTAGG 82
Db 1 ATGTGTCATGCTTTGTAGG 20
RESULT 11
AX357027
LOCUS AX357027 20 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 11 from Patent WO0206450.
ACCESSION AX357027
VERSION AX357027.1 GI:18674223
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Darimont,C., Mace,K. and Pfeifer,A.
TITLE Pre-adipose cell lines
JOURNAL Patent: WO 0206450-A 11 24-JAN-2002;
Societe des Produits Nestle S.A. (CH)
FEATURES
LOCATION/Qualifiers
SOURCE
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DNA"
Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 81 GGTACCTGGAACTTGTC 100
Db 1 GGTACCTGGAACTTGTC 20
RESULT 12
AX357028/c
LOCUS AX357028 20 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 12 from Patent WO0206450.
ACCESSION AX357028
VERSION AX357028.1 GI:18674224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Darimont,C., Mace,K. and Pfeifer,A.
TITLE Pre-adipose cell lines
JOURNAL Patent: WO 0206450-A 12 24-JAN-2002;
Societe des Produits Nestle S.A. (CH)
FEATURES
LOCATION/Qualifiers
SOURCE
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DNA"
Query Match 3.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.4; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
```

QY 471 CGTTGACCTGGACTGAAGTT 490
 Db 20 CGTTGACCTGGACTGAAGTT 1

RESULT 13/
 LOCUS AR361921/c 19 bp DNA linear PAT 17-AUG-2003
 DEFINITION Sequence 20 from patent US 6599899.
 ACCESSION AR361921
 VERSION AR361921.1 GI:33769932
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Burris,T.P. and Rybczynski,P.J.
 TITLE Benoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
 JOURNAL Patent: US 6599899-A 20 29-JUL-2003;
 FEATURES Location/Qualifiers
 source 1..19
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 3.0%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 8.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GTCATGAAGGCGTCACTT 435
 Db 19 GTCATGAAGGCGTCACTT 1

RESULT 14/
 LOCUS AX282822/c 19 bp DNA linear PAT 02-NOV-2001
 DEFINITION Sequence 36 from Patent WO0164238.
 ACCESSION AX282822
 VERSION AX282822.1 GI:16609822
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Zehentner,B., Leser-Reiff,U. and Burtcher,H.
 TITLE Methods and compositions for regulating adipocytes
 JOURNAL Patent: WO 0164238-A 36 07-SEP-2001;
 Curis, Inc. (US)
 FEATURES Location/Qualifiers
 source 1..19
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="primer"

Query Match 3.0%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 8.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 347 GCAGAAATGGATGGA AAA 365
 Db 19 GCAGAAATGGATGGA AAA 1

RESULT 15/
 LOCUS A98024/c 22 bp DNA linear PAT 26-JAN-2000
 DEFINITION Sequence 3 from Patent WO9914365.
 ACCESSION A98024
 VERSION A98024.1 GI:6781262
 KEYWORDS
 SOURCE unidentified

ORGANISM unidentified
 UNCLASSIFIED
 REFERENCE 1 (bases 1 to 22)
 AUTHORS Gerbens,P.
 TITLE THE PORCINE ADIPOCYTE FATTY ACID-BINDING PROTEIN ENCODING GENE AND METHODS TO LOCALISE, IDENTIFY OR MARK GENES OR ALLELES OR QUANTITATIVE TRAIT LOCI OF FARM ANIMALS
 JOURNAL Patent: WO 9914365-A 3 25-MAR-1999;
 STAMBOEK ZUID B.V. (NL); DALLAND B.V. (NL)
 FEATURES Location/Qualifiers
 source 1..22
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"

Query Match 3.0%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 212 CACCATTAAATCTGAAAGTACC 233
 Db 22 CACCATTAGATCAGAAAGTACC 1

RESULT 16/
 LOCUS AX154043 21 bp DNA linear PAT 22-JUN-2001
 DEFINITION Sequence 141 from Patent WO0138576.
 ACCESSION AX154043
 VERSION AX154043.1 GI:14535657
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Cargill,M., Ireland,J.S. and Lander,E.S.
 TITLE Human single nucleotide polymorphisms
 JOURNAL Patent: WO 0138576-A 141 31-MAY-2001;
 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
 FEATURES Location/Qualifiers
 source 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.7%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 15;
 Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 238 AAAATACGAGATTCCTTCA 258
 Db 1 AAAATACGAGATTCCTTCA 21

RESULT 17/
 LOCUS AX497397 21 bp DNA linear PAT 26-SEP-2002
 DEFINITION Sequence 154 from Patent WO0229058.
 ACCESSION AX497397
 VERSION AX497397.1 GI:23349687
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Shinkets,R.A., Taupier,R.J., Burgess,C.E., Zerhusen,B.D., Mezes,P.S., Rastelli,L., Malyankar,U.M., Grosse,W.M., Alsobrook,J.P., Lepley,D.M., Spytek,K.A., Li,L., Edinger,S., Gerlach,V., Ellerman,K., Macdougall,J., Gunther,E., Millet,I., Stone,D., Smithson,G. and Szekeres,E.S.
 TITLE Human proteins, polynucleotides encoding them and methods of using the same

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Zhan, J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1329 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 2.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 18;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 58 ACAAAATGTCATGC 73 17 bp DNA linear PAT 25-JUN-2003
 1 ACABAATGTCGTCG 16
 RESULT 23
 LOCUS AX762488/c 17 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 5809 from Patent WO03040369.
 ACCESSION AX762488
 VERSION AX762488.1 GI:32257104
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
 JOURNAL Patent: WO 03040369-A 5809 15-MAY-2003;
 Molecular Engines Laboratories (FR)
 FEATURES source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 2.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 18;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 615 ATAACTTTTATAGAT 630 17 bp DNA linear PAT 25-JUN-2003
 17 ATAACTTTTATAGAT 2
 RESULT 24
 LOCUS AX759766/c 17 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 3087 from Patent WO03040369.
 ACCESSION AX759766
 VERSION AX759766.1 GI:32254382
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNAL Patent: WO 03040369-A 3087 15-MAY-2003;
 Molecular Engines Laboratories (FR)
 FEATURES source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 2.2%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 346 TGCAGAAATGGGAT 359
 15 TGCAGAAATGGGAT 2
 RESULT 25
 LOCUS AX119483/c 17 bp DNA linear PAT 11-MAY-2001
 DEFINITION Sequence 140 from Patent WO0129251.
 ACCESSION AX119483
 VERSION AX119483.1 GI:14036402
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Messiaen, L. and Callens, T.
 TITLE Improved mutation analysis of the nfl gene
 JOURNAL Patent: WO 0129251-A 140 26-APR-2001;
 UNIVERSITEIT GENT (BE)
 FEATURES source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 20;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 97 TTCCAGTGAACATTT 113
 17 TTCCAGTGAACATTT 1
 RESULT 26
 LOCUS AX119539/c 17 bp DNA linear PAT 11-MAY-2001
 DEFINITION Sequence 196 from Patent WO0129251.
 ACCESSION AX119539
 VERSION AX119539.1 GI:14036458
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Messiaen, L. and Callens, T.
 TITLE Improved mutation analysis of the nfl gene
 JOURNAL Patent: WO 0129251-A 196 26-APR-2001;
 UNIVERSITEIT GENT (BE)
 FEATURES source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 2.2%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 20;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Sequence 804 from Patent WO03040369.

DEFINITION
ACCESSION AX757483
VERSION AX757483.1 GI:32252099
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijthof, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 804 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 172 CCAAACTACATGATC 188
DB 17 CAAACCCACATGATC 1
||||| |||||||

RESULT 30
AX781960/c
LOCUS AX781960
DEFINITION Sequence 291 from Patent WO03050284.
ACCESSION AX781960
VERSION AX781960.1 GI:32949809
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1
REFERENCE
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 291 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GTCCTGGTACATGTGCA 349
DB 17 GTCCTGGACATGTGCA 1
||||| |||||||

RESULT 31
AX781961/c
LOCUS AX781961
DEFINITION Sequence 292 from Patent WO03050284.
ACCESSION AX781961
VERSION AX781961.1 GI:32949810
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1
REFERENCE

2 ATTATATTC AATATG 16

Search completed: September 30, 2004, 16:29:21
Job time : 0.001 secs

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 20;
Matches 14: Conservative 0; Mismatches 1; Indels 0; Gaps 0;

586 ATTTTATTCAATATG 600
 ||| ||| ||| ||| |||
 2 ATTTATTTCAATATG 16

Query Match 2.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 20;
Matches 14. Conservative 0. Mismatches 1. Indels 0.
Gaps 0.

586 ATTTTATTCATATG 600

this Page Blank (uspio)